


=> d his

(FILE 'HOME' ENTERED AT 20:39:00 ON 16 SEP 2002)

FILE 'MEDLINE, BIOSIS' ENTERED AT 20:41:49 ON 16 SEP 2002

L1	5 S IL-17C
L2	3 DUP REM L1 (2 DUPLICATES REMOVED)
L3	0 S PRO1122
L4	16449 S (CHEN, J?)/AU
L5	2 S L1 AND L4
L6	1 S L2 AND L4
L7	0 S IL-171
L8	46 S IL-21
L9	38 DUP REM L8 (8 DUPLICATES REMOVED)
L10	0 S L9 AND IL-17
L11	18 S L9 AND PY<2000
L12	0 S PRO1031



- Drafts
- Pending
- Active
 - L4: (9) IL-17 adj (like homol\$ relat\$)
 - L5: (103598) Chen
 - L6: (49764) Chen.in.
 - L8: (86) IL adj "21"
 - L9: (5) 16 and IL-17
 - L10: (5) 16 and IL adj "17"
 - L7: (6) 16 and PRO1122
- Failed
- Saved
 - (5) IL-17C
 - (17) PRO1122
 - (16) PRO1031
- Favorites
- Tagged (0)
- UDC
- Queue
- Trash

DBs: USPAT; US-PGPUB; EPO; JPO; DERWENT

☐ Plurals

Default operator: OR

☒ Highlight all hit terms initially

16 and PRO1122

	U	1	Document ID	Issue Dat	Pages	Title	Current OR	Current XR	Retrieval	Inventor	S	C	P	3
1	<input type="checkbox"/>	<input type="checkbox"/>	US 20020127584	20020912	701	Secreted and transmembrane polypepti	435/6	435/183;		Baker, Kevin P. et al.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 20020106743	20020808		IL-17 homologous polypeptides and therap	435/69.52	435/320.1;		Chen, Jian et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 20020052027	20020502		IL-17 homologous polypeptides and therap	435/69.5	435/320.1;		Chen, Jian et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 20020010137	20010628		Novel PRO polypeptides homologous to interleuk		435/325;		ASHKENAZI, A et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 20020010137	20000323		Novel nucleic acids encoding secreted and t		435/325;		ASHKENAZI, A et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 20020052027	19991125		New polypeptides designated PRO1031 and				CHEN, J et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Ready

NUM

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 16, 2002, 15:41:36 ; Search time 30.37 seconds
(without alignments)
720.498 Million cell updates/sec

Title: US-09-854-208-3

Perfect score: 1073

Sequence: 1 MTLPLGLFLTLWLTCLAHH.....FHTEFIHVPVGTCTVLPKRSV 197

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_032802.*
1: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1980.DAT.*
2: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1981.DAT.*
3: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1982.DAT.*
4: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1983.DAT.*
5: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1984.DAT.*
6: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1985.DAT.*
7: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1986.DAT.*
8: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1987.DAT.*
9: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1988.DAT.*
10: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1989.DAT.*
11: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1990.DAT.*
12: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1991.DAT.*
13: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1992.DAT.*
14: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1993.DAT.*
15: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1994.DAT.*
16: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1995.DAT.*
17: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1996.DAT.*
18: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1997.DAT.*
19: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1998.DAT.*
20: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1999.DAT.*
21: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA2000.DAT.*
22: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1073	100.0	197	21	AA18911
2	1073	100.0	197	21	AA18911
3	1073	100.0	197	21	AA18911
4	1073	100.0	197	21	AA18911
5	1073	100.0	197	21	AA18911
6	1073	100.0	197	21	AA18911
7	1073	100.0	197	21	AA18911
8	1073	100.0	197	21	AA18911
9	1073	100.0	197	21	AA18911
10	1073	100.0	197	21	AA18911
11	1073	100.0	197	21	AA18911

12	1063	99.1	227	22	AAE08676	Human interleukin
13	1061	98.9	227	22	AAE08680	Human interleukin
14	1061	98.9	227	22	AAE08682	Human interleukin
15	1060	98.8	227	22	AAE08681	Human interleukin
16	1060	98.8	227	22	AAE08685	Human interleukin
17	1059	98.7	227	22	AAE08684	Human interleukin
18	1059	98.7	227	22	AAE08687	Human interleukin
19	1058	98.6	227	22	AAE08679	Human interleukin
20	1058	98.6	227	22	AAE08683	Human interleukin
21	1058	98.6	227	22	AAE08686	Human interleukin
22	1055	98.3	227	22	AAE08690	Human interleukin
23	1054	98.2	227	22	AAE08688	Human interleukin
24	1054	98.2	227	22	AAE08689	Human interleukin
25	1054	98.2	227	22	AAE08691	Human interleukin
26	1054	98.2	227	22	AAE08693	Human interleukin
27	1054	98.2	227	22	AAE08695	Human interleukin
28	1054	98.2	227	22	AAE08697	Human interleukin
29	1054	98.2	227	22	AAE08699	Human interleukin
30	1054	98.2	227	22	AAE08701	Human interleukin
31	1054	98.2	227	22	AAE08703	Human interleukin
32	1053	98.1	227	22	AAE08692	Human interleukin
33	1053	98.1	227	22	AAE08694	Human interleukin
34	1053	98.1	227	22	AAE08696	Human interleukin
35	1053	98.1	227	22	AAE08698	Human interleukin
36	1053	98.1	227	22	AAE08700	Human interleukin
37	1053	98.1	227	22	AAE08702	Human interleukin
38	1034	96.4	223	22	AAE08677	Human mature inter
39	459	42.8	87	21	AAV53890	Partial amino acid
40	459	42.8	87	22	AAE086119	Human interleukin
41	446	41.6	123	21	AAE07601	A human interleuki
42	446	41.6	123	21	AAE07683	A human interleuki
43	199	18.5	202	21	AAE07595	A human interleuki
44	199	18.5	202	21	AAE07689	A human interleuki
45	199	18.5	202	21	AAE07653	Human transforming

ALIGNMENTS

RESULT	1
AA18911	AA18911 standard; Protein; 197 AA.
ID	AA18911 standard; Protein; 197 AA.
XX	AA18911;
XX	AC
XX	08-FEB-2001 (first entry)
XX	A novel polypeptide designated PRO1122.
DE	Secreted protein; transmembrane protein; PRO1484; PRO4334; PRO1122;
XX	PRO1889; PRO1887; PRO1785; PRO4353; PRO4357; PRO4405; PRO4356;
KW	PRO4352; PRO4380; PRO4354; PRO4408; PRO5737; PRO4425; PRO5990; PRO6030;
KW	PRO4424; PRO4422; PRO4430; PRO4499; tumour; obesity; diabetes;
KW	insulinemia; kidney disorder; Bergers disease; nephropathy;
KW	Schönlein-Henoch purpura; celiac disease; dermatitis herpetiformis;
XX	Crohn's disease.
OS	Homo sapiens.
XX	
Key	Location/Qualifiers
FT	Peptide 1..18
FT	Region 3..25
FT	/note= "signal peptide"
FT	/note= "leucine zipper pattern"
FT	Modified-site 32..38
FT	/note= "N-myristoylation site"
FT	Modified-site 55..61
FT	/note= "N-myristoylation site"
FT	Modified-site 112..121
FT	/note= "tyrosine kinase phosphorylation site"
FT	Modified-site 133..139
XX	
PN	W0200056889-AA2.

```
XX PD 28-SEP-2000.
XX PF 01-MAR-2000; 2000WO-US05601.
XX PR 23-MAR-1999; 99US-0125774.
XX PR 23-MAR-1999; 99US-0125778.
XX PR 24-MAR-1999; 99US-0125826.
XX PR 31-MAR-1999; 99US-0127035.
XX PR 05-APR-1999; 99US-0127706.
XX PR 21-APR-1999; 99US-0130359.
XX PR 27-APR-1999; 99US-0131270.
XX PR 27-APR-1999; 99US-0131272.
XX PR 27-APR-1999; 99US-0131291.
XX PR 04-MAY-1999; 99US-0132371.
XX PR 04-MAY-1999; 99US-0132379.
XX PR 04-MAY-1999; 99US-0132383.
XX PR 25-MAY-1999; 99US-0135750.
XX PR 08-JUN-1999; 99US-0138166.
XX PR 20-JUL-1999; 99US-0144791.
XX PR 03-AUG-1999; 99US-0146970.
XX PR 09-DEC-1999; 99US-0170262.
XX PR (GETH ) GENENTECH INC.
XX PI Desnoyers L, Eaton DL, Goddard A, Godowski PJ, Gurney AL, Pan J;
XX PI Stewart TA, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2000-628263/60.
XX DR N-PSDB; AAA96338.
XX PR
XX PR Novel secreted and transmembrane polypeptides useful for diagnosing
XX PR tumour in a mammal, for identifying agonists and antagonists of the
XX PR polypeptide and for therapeutic use .
XX PS Claim 12; Fig 6; 222pp; English.
XX PR
XX CC The present sequence represents a secreted or transmembrane polypeptide.
XX -CC The specification describes polypeptides designated PRO1484, PRO4334,
XX CC PRO1122, PRO1889, PRO1890, PRO1887, PRO1785, PRO4353, PRO4357, PRO4405,
XX CC PRO4356, PRO4352, PRO4380, PRO4354, PRO4408, PRO5737, PRO4425, PRO5990,
XX CC PRO6030, PRO4424, PRO4422, PRO4430 and PRO4499. PRO1889 polypeptide is
XX CC useful for diagnosing tumour in a mammal. The polypeptides, their
XX CC agonists and antagonists are useful treating a condition associated with
XX CC expression or activity of the polypeptide. Conditions treated include
XX CC obesity, diabetes or hyper-or hypo-insulinemia. The polypeptides are
XX CC capable of inducing proliferation of mammalian kidney mesangial cells
XX CC and are therefore useful for treating kidney disorders associated with
XX CC decreased mesangial cell function such as Bergers disease or other
XX CC nephropathies associated with Schonlein-Henoch purpura, celiac disease,
XX CC dermatitis herpetiformis or Crohns disease. The nucleic acids may be used
XX CC to generate transgenic animals for use in development and screening of
XX CC therapeutically useful reagents and also for chromosome identification
XX CC and tissue typing.
XX SQ Sequence 197 AA;

Query Match 100.0%; Score 1073; DB 21; Length 197;
Best Local Similarity 100.0%; Pred. No. 4.6e-109;
Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTLPLGLLFTLWHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
Db 1 mtlplgllftlwtlhtclahhdpslrghphshgtphcysaeelpgqapphllargakwgq 60
QY 61 ALPALVSSLEASHRGHRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRYDDEDRY 120
Db 61 alpvalvssleashrgrherpsattqcpvlrpeevleadthqrsispwryrydtdedry 120
QY 121 POKLAFACELRCGICDARTGREYAAALNSVRLQSLVLRRLRRPCSDGSLPTPCAFAFHT 180
Db 121 pqklafeaelrcgcidartgreetaalnsvrlqslvllrrpcsdgsglptpgafafht 180
```

```
QY 181 EFTHVPVGCTCVLPRSV 197
Db 181 efthvpvgctcvlprsv 197

RESULT 2
AAB07602
ID AAB07602 standard; Protein; 197 AA.
XX AAB07602;
AC AAB07602;
XX 07-NOV-2000 (first entry)
DT
XX A human interleukin (IL) 171 polypeptide.
DE Interleukin; IL-17; CTLA-8; IL-170; IL-172; IL-173; IL-174; IL-176;
KW IL-177; IL-171; cell proliferation; cancer.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Peptide 1..17
XX FT /note= "signal peptide"
XX FT Protein 18..197
XX FT /note= "mature protein"
XX
XX WO200042188-A2..
XX PN
XX PD 20-JUL-2000.
XX PF 10-JAN-2000; 2000WO-US000006.
XX PR 11-JAN-1999; 99US-0228822.
XX PR (SCHE ) SCHERING CORP.
XX PI Gorman DM, Bazan JF, Kastelein RA;
XX WPI; 2000-466130/40.
XX DR N-PSDB; AAA58991.
XX
XX New isolated polynucleotide encoding a mammalian Interleukin-17 like
XX protein used to identify genes for homologous proteins -
XX
XX Disclosure; Page 20-21; 111pp; English.
XX
XX The present sequence represents an interleukin-171 (IL-171) polypeptide.
XX The polypeptide is an IL-17-like (CTLA-8 related) protein. It is a
XX member of a new group of interleukins, IL-170 polypeptides. The members
XX comprise IL-172, IL-173, IL-174, IL-176, and IL-171. IL-170
XX protein can be used to treat abnormal proliferation e.g. cancer
XX or degenerative conditions. Antibodies can be used in diagnostic
XX methods to detect over production of IL-170 protein in cells or body
XX fluids.
XX SQ Sequence 197 AA;

Query Match 100.0%; Score 1073; DB 21; Length 197;
Best Local Similarity 100.0%; Pred. No. 4.6e-109;
Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTLPLGLLFTLWHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
Db 1 mtlplgllftlwtlhtclahhdpslrghphshgtphcysaeelpgqapphllargakwgq 60
QY 61 ALPALVSSLEASHRGHRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRYDDEDRY 120
Db 61 alpvalvssleashrgrherpsattqcpvlrpeevleadthqrsispwryrydtdedry 120
QY 121 POKLAFACELRCGICDARTGREYAAALNSVRLQSLVLRRLRRPCSDGSLPTPCAFAFHT 180
Db 121 pqklafeaelrcgcidartgreetaalnsvrlqslvllrrpcsdgsglptpgafafht 180
```


Query Match 100.0%; Score 1073; DB 21; Length 197;
Best Local Similarity 100.0%; Pred. No. 4.6e-109;
Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTLPLGLLFLTWLHTCLAHDPRLGRHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
|||||
Db 1 mtlplgllfltlwhtclahdpslrghpshgtphcysaeelpigqapphillargakwgq 60
|||||

QY 61 ALPVALVSSLEAASHRGHERPSATTQCPVLRPEEVLEADTHQRSISPMRYRVDTDEDY 120
|||||
Db 61 alpvalvssleaaashrgherpsattqcpvlrpeevleadthqrsispmryrvdtdedry 120
|||||

QY 121 POKLAFACLCRCGCDARTGRETALNSVRLQLSLLVLRPPCSRDGSGSLPTPGAFAPFT 180
|||||
Db 121 pqklafaelcrgcdartgretaalnsvrlqlslvlrrppcsrdgsgslptpgafafht 180
|||||

QY 181 EFIHVPVGCCTCVLPRSV 197
|||||
Db 181 efihvpvgctcvlprsv 197
|||||

RESULT 5
AAI44460
ID AAY44460 standard; Protein; 197 AA.
XX
AC AAY44460;
XX
DT 27-MAR-2000 (first entry)
XX
DE Human Interleukin 17C, PRO1122 polypeptide.
XX
-KW Interleukin; IL-17C; PRO1122 polypeptide; clone DNA62377-1381-1; UNQ561;
KW cytokine IL-17; cytotoxic T-lymphocyte-associated antigen 8; CTLA-8;
KW hybridisation probe; antagonist; degenerative cartilaginous disorder;
KW agonist; diagnosis; therapy.
XX
-OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..18
FT Protein 19..197
FT FT /label= Mature_IL-17C_polypeptide
FT FT /note= "Used to treat degenerative cartilaginous
FT FT disorder"
FT FT Misc-difference 109 /note= "Conserved Trp residue"
FT FT Misc-difference 129 /note= "Conserved Cys residue"
FT FT Misc-difference 134 /note= "Conserved Cys residue"
FT FT Misc-difference 163 /note= "Conserved Cys residue"
FT FT Misc-difference 189 /note= "Conserved Cys residue"
FT FT Misc-difference 191 /note= "Conserved Cys residue"
XX WO9960127-A2.
XX
XX 25-NOV-1999.
XX
XX 14-MAY-1999; 99WO-US10733.
XX
XX 15-MAY-1998; 98US-0085579.
XX 23-DEC-1998; 98US-0113621.
XX
XX (GETH) GENENTECH INC.
XX
XX Chen J, Filvaroff E, Goddard A, Gurney AL, Li H, Wood WI;
XX

DR WPI; 2000-116314/10.
XX N-PSDB; AAZ29728.
PT New polypeptides designated PRO1031 and PRO1122 used to treat a
FT degenerative cartilaginous disorder -
XX
XX Claim 23; Fig 3; 141pp; English.
XX
XX The present sequence is the human PRO1122 polypeptide, also referred to
CC as UNQ561, and as interleukin-17C (IL-17C), encoded by
CC clone DNA62377-1381-1. This sequence has identity with the
CC cytokine IL-17 and cytotoxic T-lymphocyte-associated antigen 8 (CTLA-8)
CC and has leucine zipper pattern. PRO1122 is expressed in pancreas, small
CC intestine, stomach and testis also. It shares about 26-28% amino acid
CC identity with IL-17 and IL-17B. The entire coding region of IL-17C can
CC be used as hybridisation probe. The PRO1122 polypeptide, agonist or
CC antagonist, is used to diagnose and treat a degenerative cartilaginous
CC disorder.
XX
XX Sequence 197 AA;
SQ

Query Match 100.0%; Score 1073; DB 21; Length 197;
Best Local Similarity 100.0%; Pred. No. 4.6e-109;
Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTLPLGLLFLTWLHTCLAHDPRLGRHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
|||||
Db 1 mtlplgllfltlwhtclahdpslrghpshgtphcysaeelpigqapphillargakwgq 60
|||||

QY 61 ALPVALVSSLEAASHRGHERPSATTQCPVLRPEEVLEADTHQRSISPMRYRVDTDEDY 120
|||||
Db 61 alpvalvssleaaashrgherpsattqcpvlrpeevleadthqrsispmryrvdtdedry 120
|||||

QY 121 POKLAFACLCRCGCDARTGRETALNSVRLQLSLLVLRPPCSRDGSGSLPTPGAFAPFT 180
|||||
Db 121 pqklafaelcrgcdartgretaalnsvrlqlslvlrrppcsrdgsgslptpgafafht 180
|||||

QY 181 EFIHVPVGCCTCVLPRSV 197
|||||
Db 181 efihvpvgctcvlprsv 197
|||||

RESULT 6
AAI53892
ID AAY53892 standard; Protein; 197 AA.
XX
AC AAY53892;
XX
DT 13-MAR-2000 (first entry)
XX
DE Amino acid sequence of human interleukin-21.
XX
KW Human; interleukin-22; IL-22; IL-21; immune system disorder;
KW immune cell chemotaxis; haematopoietic cell disorder;
KW haemostatic activity; thrombolytic activity; autoimmune disorder; asthma;
KW respiratory problem; organ rejection; graft-versus-host disease; GVHD;
KW inflammation; hyperproliferative disorder; tissue regeneration;
KW embryonic stem cell differentiation; embryonic stem cell proliferation;
KW haematopoietic lineage; allergic asthma.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..18 /note= "signal peptide"
FT Domain 34..40 /note= "conserved domain V"
FT Domain 63..68 /note= "conserved domain VI"
FT Domain 104..109 /note= "conserved domain VII"
FT Domain 113..121

FT FT /note= "conserved domain I" 129..134
 FT FT /note= "conserved domain II" 156..162
 FT FT /note= "conserved domain III" 185..192
 FT FT /note= "conserved domain IV" 197..204
 XX XX WO9961617-A1.
 PN 02-DEC-1999.
 PD 27-MAY-1999; 99WO-US11644.
 XX 29-MAY-1998; 98US-0087340.
 PR 10-SEP-1998; 98US-0099805.
 PR 30-APR-1999; 99US-0131965.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA Ruben SM, Ebner R;
 PI WPI: 2000-072622/06.
 XX N-PSDB; AAZ36836.
 DR Novel polynucleotides used to develop products for treating e.g. immune
 XX disorders, blood disorders, autoimmune disorders, allergies,
 PT inflammation, hyperproliferative disorders or infections -
 PT Claim 26; Fig 6A-B; 170pp; English.
 PS The present sequence represents a human interleukin-21 (IL-21)
 CC protein. The specification also describes IL-22 polynucleotides and
 CC polypeptides. The IL-21 polynucleotide was isolated from a cDNA library
 CC of apoptotic T-cells. IL-21 and IL-22 may be useful in treating
 CC deficiencies or disorders of the immune system, by activating or
 CC inhibiting the proliferation, differentiation, or mobilization
 CC (chemotaxis) of immune cells, treating or detecting deficiencies or
 CC disorders of haematopoietic cells, to modulate haemostatic or
 CC thrombolytic activity, in treating or detecting autoimmune disorders,
 CC treating asthma (particularly allergic asthma) or other respiratory
 CC problems, to treat and/or prevent organ rejection or graft-versus-host
 CC disease (GVHD), to modulate inflammation, to treat or detect
 CC hyperproliferative disorders, to treat or detect infectious agents, to
 CC differentiate, proliferate and attract cells, leading to the
 CC regeneration of tissues, IL-21 and IL-22 may also increase or decrease
 CC the differentiation or proliferation of embryonic stem cells and
 CC haematopoietic lineage, may be used to modulate mammalian
 CC characteristics.
 XX SQ Sequence 197 AA;
 Query Match 100.0%; Score 1073; DB 21; Length 197;
 Best Local Similarity 100.0%; Pred. No. 4.6e-109;
 Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTLPLGLFTLWLTCLAHDPSSLRGHPHSGTGHPCYSAEELPLGOAPPHLLARGAKWGQ 60
 Db 1 mtlplglflwtclahdpsslrghphsgtghpcysaeelp19gapphllargakwgq 60
 QY 61 ALPALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHQRTSPWRYRVDTDDEY 120
 Db 61 alpavlvssleashrgrherpsattqcpvrpeevleadthqrsipwryrvdtdedry 120
 QY 121 POKLAFACELRCGIDARTGRTAALNSVRLQLSLVLRPPCRSGSLPTGCAFAFHT 180
 Db 121 pqklafaelcrgcidartgretaalnsvrlqlslvrrpcrsdsgslptpgafafht 180
 QY 181 EFTHVPVGCTCVLPVRSV 197
 Db 181 efihvpvgctcvlpvrsv 197

RESULT 7

AAG66121
 ID AAG66121 standard; Protein; 197 AA.
 XX
 AC AAG66121;
 XX 13-MAR-2002 (first entry)
 DT Human interleukin (IL)-21 amino acid sequence.
 XX
 DE Interleukin; IL-21; IL-22; immunosuppressive; cytostatic; thrombolytic;
 KW antiinflammatory; antibacterial; gene therapy; human.
 XX
 OS Homo sapiens.
 XX
 PH Key Location/Qualifiers
 FT 1..18 Peptide /note= "signal peptide"
 FT 19..197 Protein /note= "mature protein"
 FT 34..40 Domain /note= "conserved domain V"
 FT 63..68 Domain /note= "conserved domain VI"
 FT 104..109 Domain /note= "conserved domain VII"
 FT 113..121 Domain /note= "conserved domain I"
 FT 129..134 Domain /note= "conserved domain II"
 FT 156..162 Domain /note= "conserved domain III"
 FT 185..192 Domain /note= "conserved domain IV"
 XX US2001023070-A1.
 PN 20-SEP-2001.
 PD 08-DEC-2000; 2000US-0731816.
 XX 29-MAY-1998; 98US-087340P.
 PR 30-APR-1999; 99US-131965P.
 PR 09-DEC-1999; 99US-169837P.
 PR 27-MAY-1999; 99US-0320713.
 PR 27-MAY-1999; 99WO-US11644.
 XX (EBNE/) EBNER R.
 PA (RUBE/) RUBEN S M.
 XX
 PI Ebner R, Ruben SM;
 XX WPI: 2001-638470/73.
 DR N-PSDB; AAI67878.
 XX New interleukin-21 and interleukin-22 polynucleotides and polypeptides,
 PT useful for treating, preventing or diagnosing e.g. disorders of
 PT hematopoietic cells, autoimmune disorders, or hyperproliferative
 PT diseases -
 XX Claim 26; Fig 6A-B; 87pp; English.
 PS The invention relates to novel human proteins designated interleukin
 CC (IL)-21 and IL-22. The IL-21 and IL-22 polynucleotides can be used in
 CC linkage analysis as a marker for those specific chromosomes, in chromosome
 CC mapping, to control gene expression through triple helix formation or
 CC antisense DNA or RNA, in gene therapy, in identifying individuals from
 CC minute biological samples, as an alternative to restriction fragment
 CC length polymorphism (RFLP) analysis, as polymorphic markers for forensic
 CC purposes, as molecular weight markers, or as diagnostic probes. IL-21 and
 CC IL-22 polypeptides can be used to treat, prevent or diagnose diseases of
 CC the immune system by activating or inhibiting the proliferation,

CC differentiation or mobilization of immune cells, disorders of
CC hematopoietic cells (e.g. ataxia, human immunodeficiency virus (HIV)
CC infection, anemia, thrombocytopenia), autoimmune disorders (e.g. Grave's
CC disease, systemic lupus erythematosus, ophthalmia), graft versus host
CC diseases, inflammation, hyperproliferative disorders, or infectious
CC diseases. The polypeptides are useful for generating antibodies, which
CC can be used to treat, inhibit or prevent diseases or conditions
CC associated with aberrant expression and/or activity of IL-21 or IL-22.
CC The present sequence represents the amino acid sequence of human IL-21.
XX
SQ Sequence 197 AA;

Query Match 100.0%; Score 1073; DB 22; Length 197;
Best Local Similarity 100.0%; Pred. No. 4 6e-109;
Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTLPLGLLFTLWHTCLAHDPISLRGPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
Db 1 mtlplgllftlwtclahdpslrghphshgtphcysaeelpigqapphllargakwgq 60
Qy 61 ALPALVSSLEAASHRGHERPSATTCQPVLRPEEVLADTHQRSISPWRYRVDTDEDRY 120
Db 61 alpvalvssleaaashrgherpsattcqpvlrpeeleadthqrsispwryrvdtdeary 120
Qy 121 PQKLAFAECLRCGCTDARTGRTAALNSVRLQLSLVLLRRRRCSDGSLPTPGAFAFHT 180
Db 121 pqklafaeclrcgctdartgretaalnsvrlqlslvllrrrrpcsdrgslptpgafafht 180
Qy 181 EFIHVPVCTCVALPRSV 197
Db 181 efihvpvctcvalprsv 197

RESULT 8
AAU29247
ID AAU29247 standard; Protein; 197 AA.
XX
-AC AAU29247;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human PRO polypeptide sequence #224.
XX
KW PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200168848-A2.
XX
PD 20-SEP-2001.
XX
PF 28-FEB-2001; 2001WO-US06520.
XX

XX 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05841.
PR 03-MAR-2000; 2000US-187202P.
PR 06-MAR-2000; 2000US-186968P.
PR 14-MAR-2000; 2000US-189320P.
PR 14-MAR-2000; 2000US-189320P.
PR 15-MAR-2000; 2000WO-US06884.
PR 21-MAR-2000; 2000US-190828P.
PR 21-MAR-2000; 2000US-191007P.
PR 21-MAR-2000; 2000US-191048P.
PR 21-MAR-2000; 2000US-191314P.
PR 28-MAR-2000; 2000US-192655P.
PR 29-MAR-2000; 2000US-193032P.
PR 29-MAR-2000; 2000US-193053P.
PR 30-MAR-2000; 2000WO-US08439.
PR 04-APR-2000; 2000US-194449P.

PR 04-APR-2000; 2000US-194647P.
PR 11-APR-2000; 2000US-195975P.
PR 11-APR-2000; 2000US-196000P.
PR 11-APR-2000; 2000US-196187P.
PR 11-APR-2000; 2000US-196690P.
PR 11-APR-2000; 2000US-196820P.
PR 18-APR-2000; 2000US-198121P.
PR 18-APR-2000; 2000US-198585P.
PR 25-APR-2000; 2000US-199397P.
PR 25-APR-2000; 2000US-199550P.
PR 25-APR-2000; 2000US-199654P.
PR 03-MAY-2000; 2000US-201516P.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 05-JUN-2000; 2000US-209832P.
PR 28-JUL-2000; 2000WO-US20710.
PR 22-AUG-2000; 2000US-0644848.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
XX

(GETH) GENENTECH INC.
XX
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PI
PI
XX
DR WPI; 2001-602746/68.
DR N-PSDB; AAS4614B.

XX Novel nucleic acids encoding PRO polypeptides, used to diagnose the
PT presence of tumours, such as prostate and breast tumours, in mammals and
PT to screen for modulators of the compounds -
XX
PS Claim 11; Fig 448; 774pp; English.

XX Sequences AAU29024-AAU29328 represent PRO polypeptides of the invention.
CC The PRO polypeptides and their associated nucleic acids can be used to
CC detect the presence of a tumour in a mammal by comparing the level of
CC expression of a PRO polypeptide in a test sample of cells from the animal
CC and a control sample of normal cells, whereby a higher level of
CC expression in the test sample indicates the presence of a tumour in the
CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats
CC and rabbits but are preferably human. The polypeptides can be used to
CC stimulate tumour necrosis factor (TNF) alpha release from human blood,
CC when contacted with it. A specific polypeptide can be used to stimulate
CC the proliferation or differentiation of chondrocyte cells. The PRO
CC proteins can be used to determine the presence of tumours and also
CC susceptibility to tumour development, particularly adrenal, lung, colon,
CC breast, prostate, rectal, cervical, or liver tumours, in mammalian
CC subjects. The oligonucleotide probes specific for the PRO nucleic acids
CC can be used for genetic analysis of individuals with genetic disorders.
XX

SQ Sequence 197 AA;

Query Match 100.0%; Score 1073; DB 22; Length 197;
Best Local Similarity 100.0%; Pred. No. 4 6e-109;
Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTLPLGLLFTLWHTCLAHDPISLRGPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
Db 1 mtlplgllftlwtclahdpslrghphshgtphcysaeelpigqapphllargakwgq 60
Qy 61 ALPALVSSLEAASHRGHERPSATTCQPVLRPEEVLADTHQRSISPWRYRVDTDEDRY 120
Db 61 alpvalvssleaaashrgherpsattcqpvlrpeeleadthqrsispwryrvdtdeary 120
Qy 121 PQKLAFAECLRCGCTDARTGRTAALNSVRLQLSLVLLRRRRCSDGSLPTPGAFAFHT 180
Db 121 pqklafaeclrcgctdartgretaalnsvrlqlslvllrrrrpcsdrgslptpgafafht 180

QY 181 EFHVPVGCCTVLPVRSV 197
 Db 181 efihvpvgctcvlprsv 197

RESULT 9
 AAU04951
 ID AAU04951 standard; Protein; 197 AA.
 XX
 AC AAU04951;
 XX 24-OCT-2001 (first entry)
 XX Human Interleukin 17C ligand, IL-17C.
 DE Human; Interleukin-17C ligand; IL-17C; agonist; antagonist;
 KW PRO1122; DNA 62377-1381-1; systemic lupus erythematosus;
 KW rheumatoid arthritis; osteoarthritis; diabetes mellitus;
 KW allergic disease; asthma; demyelinating disease;
 KW degenerative cartilaginous disorder; transplantation associated disease.
 XX Homo sapiens.
 OS

Key Location/Qualifiers
 FH Peptide 1..18
 FT /label= Signal_peptide
 FT Region 3..25
 FT /note= "Leucine zipper pattern"
 FT Protein 19..197
 FT /label= Mature_IL_17C
 FT Region 32..38
 FT /note= "N-myristoylation site"
 FT Region 55..61
 FT /note= "N-myristoylation site"
 FT Region 99..125
 FT /note= "Region homologous to IL-17"
 FT Region 112..121
 FT /note= "Tyrosine kinase phosphorylation site"
 FT Region 133..139
 FT /note= "N-myristoylation site"
 XX W020014620-A2.
 PN
 XX
 PD 28-JUN-2001.
 XX
 XX 20-DEC-2000; 2000WO-US34956.
 XX
 XX 23-DEC-1999; 99US-0172096.
 PR 30-DEC-1999; 99WO-US31274.
 PR 11-JAN-2000; 2000US-0175481.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 21-MAR-2000; 2000US-0191007.
 PR 21-MAR-2000; 2000WO-US07532.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 22-JUN-2000; 2000US-0213087.
 PR 22-AUG-2000; 2000US-064848.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 24-OCT-2000; 2000US-0242837.
 PR 10-NOV-2000; 2000WO-US30873.
 PR 28-NOV-2000; 2000US-0253646.
 PR 01-DEC-2000; 2000WO-US32678.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Chen J, Filvaroff E, Fong S, Goddard A, Godowski PJ, Grimaldi CU;
 PI Guney AL, Li H, Hillan KJ, Tumas D, Van Lookeren M, Vanden RL;
 PI Watanabe CK, Williams PM, Wood WI, Yansura DG;
 XX WPI; 2001-451708/48.
 DR N-PSDB; AAS09510.
 XX

Novel PRO polypeptides homologous to interleukin-17, useful for the diagnosis and treatment of immune related disease e.g. rheumatoid arthritis and diabetes -

Claim 10; Fig 4; 188pp; English.

The sequence is PRO1122 which is the human Interleukin 17C ligand, IL-17C, encoded by DNA 62377-1381-1. A composition containing ant/agonists to the PRO polypeptides or individual components are useful for treating a mammal with an immune related disease, e.g. systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, a spondyloarthropathy, systemic sclerosis, an idiopathic inflammatory myopathy, Sjogren's syndrome, systemic vasculitis, sarcoidosis, thyroiditis, diabetes mellitus, immune-mediated renal thrombocytopaenia, contact dermatitis, an autoimmune or immune-mediated skin disease, a demyelinating disease, an allergic disease e.g. food hypersensitivity, asthma, a transplantation associated disease, or a chronic inflammatory demyelinating polyneuropathy. Treating a degenerative cartilaginous disorder comprises administering a PRO1031 or PRO1122 polypeptide agonist, or antagonist to the mammal. Numerous examples of the diseases and disorders are given in the specification.

XX Sequence 197 AA;

Query Match 100.0%; Score 1073; DB 22; Length 197;
 Best Local Similarity 100.0%; Pred. No. 4 6e-109;
 Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTLPLGLLFTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLARGAKWGQ 60
 Db 1 mtlplgllftwlhtclahhdpslrghphshgtpchysaeelpigqapphllargakwgq 60
 QY 61 ALPVALYSSLEAASHRGHRPSPATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDY 120
 Db 61 alpvalyssleashaahrghrpsattqcpvlrpeevleadtqrsispwryrvdtdedy 120
 QY 121 PQLAFACLCRCGICDARTGRTAALNSVRLQLSLVLRPPCRDGLPTPGAFAPHT 180
 Db 121 pqlafaelcrgicidartgretaalnsvrlqslvllrrpcrdsgslptpgafafht 180
 QY 181 EFHVPVGCCTVLPVRSV 197
 Db 181 efihvpvgctcvlprsv 197

RESULT 10
 AAU44485
 ID AAU44485 standard; Protein; 206 AA.
 XX
 AC AAU44485;
 XX 27-MAR-2000 (first entry)
 XX Human Interleukin 17C with C-terminal Gly(His)8 tag, IL-17C.his.
 DE
 DE Interleukin: IL-17C.his; PRO1122 polypeptide; clone DNA62377-1381-1;
 KW Immunoprecipitation; IL-17 receptor extracellular domain; IL-17R ECD;
 KW cytokine IL-17; hybridisation probe; antagonist; Gly(His)8 tag; agonist;
 KW degenerative cartilaginous disorder; diagnosis; therapy.
 XX Homo sapiens.
 OS

Key Location/Qualifiers
 FH Peptide 1..18
 FT /label= Signal_peptide
 FT Protein 19..197
 FT /label= Mature_IL-17C_polypeptide
 FT /note= "Used to treat degenerative cartilaginous disorder"
 FT Misc-difference 109
 FT /note= "Conserved Trp residue"

FT Misc-difference 129 /note= "Conserved Cys residue"
FT Misc-difference 134 /note= "Conserved Cys residue"
FT Misc-difference 163 /note= "Conserved Cys residue"
FT Misc-difference 189 /note= "Conserved Cys residue"
FT Misc-difference 191 /note= "Conserved Cys residue"
FT Misc-difference 198..206 /note= "Conserved Cys residue"
FT /note= "C-terminal Gly(His)8 tag"
XX
PN WO9960127-A2.
XX
PD 25-NOV-1999.
XX
PF 14-MAY-1999; 99WO-US10733.
XX
XX 15-MAY-1998; 98US-0085579.
PR 23-DEC-1998; 98US-0113621.
XX
PA (GETH) GENENTECH INC.
XX
PI Chen J, Filvaroff E, Goddard A, Gurney AL, Li H, Wood WI;
XX
DR WPI; 2000-116314/10.
XX
PT New polypeptides designated PRO1031 and PRO1122 used to treat a
PT degenerative cartilaginous disorder -
XX
PS Example 11; Page 138-139; 141pp; English.
XX
-CC The present sequence is the human PRO1122 polypeptide, with a C-terminal
CC Gly(His)8 tag, IL-17C his, derived from the clone DNA62377-1381-1.
CC This sequence is used in a competitive binding experiment for the
CC immunoprecipitation of IL-17 receptor extracellular domain (IL-17R ECD).
-CC The entire coding region of IL-17C can be used as hybridisation probe.
CC The PRO1122 polypeptide, agonist or antagonist, is used to diagnose and
CC treat a degenerative cartilaginous disorder.
XX
SQ Sequence 206 AA;

Query Match 100.0%; Score 1073; DB 21; Length 206;
Best Local Similarity 100.0%; Pred. No. 4.9e-109;
Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTLPLGLLFTLWHTCLAHDPSSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
Db 1 mtlplgllfltlwhtclahdpsslrghphshgtphcysaeelpigqapphllargakwgq 60

QY 61 ALPVALVSSLEAASHRGHERPSATTQCPVLRPEEVLADTHQRSISPMRYRVDTDEDRY 120
Db 61 alpvalvssleaaashrgherpsattqcpvlrpeeleadthqrsispmryrvdtdedry 120

QY 121 POKLAFAECLRCGCDARTGTRETAALNSVRLQLSLVLRPPCRSDGSLPTPGAFAPHT 180
Db 121 pqklafaeclrcgcidartgtretaalnsvrlqlslvlrrppcrsdgslptpgafafht 180

QY 181 EFHVPVGTCTVLPVRSV 197
Db 181 efhvpvgctcvlprsv 197

RESULT 11
ID AAY44462 standard; Protein; 425 AA.
XX
AC AAY44462;
XX
XX 27-MAR-2000 (first entry)
XX

DE Human Interleukin 17C-IgG1 Fc fusion protein, hIL-17C.fc.
XX
KW Interleukin; IL-17C.fc: fusion protein; PRO1122 polypeptide; cytokine;
KW human IgG1; fluorescence-activated cell sorter analysis; FACS;
KW Tumour Necrosis Factor-alpha; TNF-alpha; leukemic monocyte; THP-1 cell.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..18
FT Protein /label= Signal_peptide
FT /label= Mature_IL-17C_polypeptide
FT /note= "Used to treat degenerative cartilaginous
FT disorder"
FT Misc-difference 109 /note= "Conserved Trp residue"
FT Misc-difference 129 /note= "Conserved Cys residue"
FT Misc-difference 134 /note= "Conserved Cys residue"
FT Misc-difference 163 /note= "Conserved Cys residue"
FT Misc-difference 189 /note= "Conserved Cys residue"
FT Misc-difference 191 /note= "Conserved Cys residue"
FT Region 197..425
FT /note= "Sequence derived from Fc region of human IgG1"
XX
PN WO9960127-A2.
XX
XX 25-NOV-1999.
PD
XX 14-MAY-1999; 99WO-US10733.
PF
XX 15-MAY-1998; 98US-0085579.
PR 23-DEC-1998; 98US-0113621.
XX
PA (GETH) GENENTECH INC.
XX
PI Chen J, Filvaroff E, Goddard A, Gurney AL, Li H, Wood WI;
XX
DR WPI; 2000-116314/10.
XX
PT New polypeptides designated PRO1031 and PRO1122 used to treat a
PT degenerative cartilaginous disorder -
XX
PS Example 12; Page 129-130; 141pp; English.
XX
-CC The present sequence is the human IL-17C.fc fusion protein, derived from
CC PRO1122 polypeptide and the Fc region of human IgG1. The cytokine IL-17C
CC can be used to induce the release of TNF-alpha from human leukemic
CC monocytic, THP-1 cells. The fusion protein, IL-17C.fc is used to identify
CC the binding of IL-17C to THP-1 cells, using fluorescence-activated cell
CC sorter analysis (FACS).
XX
SQ Sequence 425 AA;

Query Match 100.0%; Score 1073; DB 21; Length 425;
Best Local Similarity 100.0%; Pred. No. 1.3e-108;
Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTLPLGLLFTLWHTCLAHDPSSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
Db 1 mtlplgllfltlwhtclahdpsslrghphshgtphcysaeelpigqapphllargakwgq 60

QY 61 ALPVALVSSLEAASHRGHERPSATTQCPVLRPEEVLADTHQRSISPMRYRVDTDEDRY 120
Db 61 alpvalvssleaaashrgherpsattqcpvlrpeeleadthqrsispmryrvdtdedry 120

QY 121 POKLAFAECLRCGCDARTGTRETAALNSVRLQLSLVLRPPCRSDGSLPTPGAFAPHT 180

|||||
Db 121 pqlafaelcrgcidartgretaaalnsrvllqslvlrrpcsdgsgiptgafah 180
QY 181 EFIHVPVGCVCVLPVRSV 197
Db 181 efihvpvgctcvlprsv 197

RESULT 12
AAE08676
ID AAE08676 standard; Protein; 227 AA.
XX AAE08676;
XX 15-NOV-2001 (first entry)
XX Human interleukin (IL)-17 like protein.
XX
XX Human; Interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic.
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH Peptide 5..48
FT /label= Signal_peptide
FT Protein 49..227
FT /label= Mature_human_IL-17_like protein
XX
XX WO200159120-A2.
PN
XX
PD 16-AUG-2001.
XX
PF 07-FEB-2001; 2001WO-US03916.
XX
PR 08-FEB-2000; 2000US-0180864.
PR 27-NOV-2000; 2000US-0722920.
XX
PA (AMGE-) AMGEN INC.
XX
PI Jing S, Bass MB;
XX
XX WPI; 2001-529841/58.
DR N-PSDB; AADI5291.
XX
XX Novel interleukin-17 like polypeptides and nucleic acid molecules
PT encoding them useful for diagnosis, prevention and treatment of
PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT rejection -
XX
PS Claim 14; Fig 1A; 117pp; English.
XX
XX The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in

CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like protein.
XX
SQ Sequence 227 AA;

Query Match 99.1%; Score 1063; DB 22; Length 227;
Best Local Similarity 100.0%; Pred. No. 6.9e-108;
Matches 195; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 LLPGLFLTWLHTCLAHDPFSLRGHPHSHGTPHCYSAEELPLGQAPPPLLARGAKWQAL 62
Db 33 llpgllfltlwhtclahhdpfslrgphshgtphcysaeelpgqapphllargakwqal 92

QY 63 PVALVSSLEAASHRGHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDYPO 122
Db 93 pvalvssleaaashrgrherpsattqcpvlrpeevleadhqrsispwryrvdtdedryp 152

QY 123 KLAFACELCRGCDARTGRTAALNSVRLQLSLVLRPPCRSDSGLPFGAFAFHTEF 182
Db 153 klafaelcrgcidartgretaaalnsrvllqslvlrrpcsdgsglptpgafafhtef 212

QY 183 IHVPVGCTCVLPVRSV 197
Db 213 ihvpvgctcvlprsv 227

RESULT 13
AAE08680
ID AAE08680 standard; Protein; 227 AA.
XX AAE08680;
XX 15-NOV-2001 (first entry)
XX Human interleukin (IL)-17 like protein mutant (Leu47Ile).
XX
XX Human; Interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Misc-difference 47
FT /note= "Wild-type Leu substituted with Ile"
XX
XX WO200159120-A2.
XX
XX 16-AUG-2001.
XX
XX 07-FEB-2001; 2001WO-US03916.
XX
XX 08-FEB-2000; 2000US-0180864.
PR 27-NOV-2000; 2000US-0722920.
XX
XX (AMGE-) AMGEN INC.
XX
XX Jing S, Bass MB;
XX WPI; 2001-529841/58.
XX
XX Novel interleukin-17 like polypeptides and nucleic acid molecules
PT encoding them useful for diagnosis, prevention and treatment of
PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT rejection -
XX

PS Claim 18; Page -: 117pp; English.

xx The present invention relates to interleukin (IL)-17 like polypeptides and nucleic acids encoding them. IL-17 like protein is useful for identifying binding partners, agonists and antagonists which can be used for treating one or more diseases or disorders and for cloning IL-17 like receptors, using an expression cloning strategy. Radiolabelled or affinity/activity-tagged IL-17 proteins are useful in binding assays to identify a cell type or cell line or tissue that express IL-17 like receptors. A radiolabelled or tagged IL-17 like protein is useful as an affinity ligand to identify and isolate from an expression library the subset of cells which express the IL-17 like receptors on their surface. IL-17 like protein, agonist and antagonist are useful for treating acute and chronic inflammation such as rheumatic diseases, graft versus host disease and multiple sclerosis. IL-17 like antagonists are useful for treating and preventing inflammatory disease, autoimmune disease, allergies, asthma and organ or graft rejection in a patient and also for inhibiting T cell proliferation and/or activation, in vivo B cell proliferation or immunoglobulin secretion, and for blocking the effects of IL-17 in inducing bone destruction. IL-17 like molecule is useful in gene therapy and for mapping the location of the IL-17 like gene and related genes on chromosomes, as hybridisation probes in diagnostic assays. Non-human animals in which the promoter for one or more of IL-17 like protein is either activated or inactivated are useful for drug candidate screening. The present sequence is human IL-17 like protein mutant (Leu47Ile).

cc Note: The present sequence is not shown in the specification, but is derived from the human IL-17 like protein referred to as SEQ ID NO:2 (AAE08676), shown in figure 1A.

xx Sequence 227 AA;

Query Match 98.9%; Score 1061; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 1.1e-107;
Matches 194; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 LLPGLLFTWLHTCLAHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
Db 33 llpgllflftwlhtclahdpshlrgphshgtphcysaeelpglgqapphllargakwgqal 92

Qy 63 PVALVSSLEAASHRGHERPSATTQCPVLRPEEVLADTHORSISPWRYVDTDDEDRYPQ 122
Db 93 pvalvssleaaashrgherpsattqcpvlrpeevleadtorsispswryrvdtdedrypq 152

Qy 123 KLAFACLCRCIDARTGRETAALNSVRLQSLVLRPPCSRDGSGGLPTPGAFAFHTEF 182
Db 153 klafaelcrlcridartgretaalnsvrlqslvlrrppcsrdgsglptpgafafhtef 212

Qy 183 IHVPVGCTCVLPKRSV 197
Db 213 ihvpvgctcvlprsv 227

RESULT 14
AAE08682
ID AAE08682 standard; Protein: 227 AA.

XX AAE08682;
XX
DT 15-NOV-2001 (first entry)
XX
DE Human interleukin (IL)-17 like protein mutant (Leu47Met).

KW Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; anti-allergic; mutant; mutein.
OS Homo sapiens.
OS Synthetic.

FH Key Location/Qualifiers
FT Misc-difference 47 /note= "Wild-type Leu substituted with Met"
XX WO200159120-A2.
XX 16-AUG-2001.
XX 07-FEB-2001; 2001WO-US03916.
XX 08-FEB-2000; 2000US-0180864.
XX 27-NOV-2000; 2000US-0722920.
XX (AMGE-) AMGEN INC.
XX Jing S, Bass MB;
XX WPI; 2001-529841/58.
XX Novel interleukin-17 like polypeptides and nucleic acid molecules encoding them useful for diagnosis, prevention and treatment of inflammatory, autoimmune disease, allergies, asthma and organ or graft rejection.
XX Claim 18; Page -: 117pp; English.
XX The present invention relates to interleukin (IL)-17 like polypeptides and nucleic acids encoding them. IL-17 like protein is useful for identifying binding partners, agonists and antagonists which can be used for treating one or more diseases or disorders and for cloning IL-17 like receptors, using an expression cloning strategy. Radiolabelled or affinity/activity-tagged IL-17 proteins are useful in binding assays to identify a cell type or cell line or tissue that express IL-17 like receptors. A radiolabelled or tagged IL-17 like protein is useful as an affinity ligand to identify and isolate from an expression library the subset of cells which express the IL-17 like receptors on their surface. IL-17 like protein, agonist and antagonist are useful for treating acute and chronic inflammation such as rheumatic diseases, graft versus host disease and multiple sclerosis. IL-17 like antagonists are useful for treating and preventing inflammatory disease, autoimmune disease, allergies, asthma and organ or graft rejection in a patient and also for inhibiting T cell proliferation and/or activation, in vivo B cell proliferation or immunoglobulin secretion, and for blocking the effects of IL-17 in inducing bone destruction. IL-17 like molecule is useful in gene therapy and for mapping the location of the IL-17 like gene and related genes on chromosomes, as hybridisation probes in diagnostic assays. Non-human animals in which the promoter for one or more of IL-17 like protein is either activated or inactivated are useful for drug candidate screening. The present sequence is human IL-17 like protein mutant (Leu47Met).

cc Note: The present sequence is not shown in the specification, but is derived from the human IL-17 like protein referred to as SEQ ID NO:2 (AAE08676), shown in figure 1A.

xx Sequence 227 AA;

Query Match 98.9%; Score 1061; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 1.1e-107;
Matches 194; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 LLPGLLFTWLHTCLAHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
Db 33 llpgllflftwlhtclahdpshlrgphshgtphcysaeelpglgqapphllargakwgqal 92

Qy 63 PVALVSSLEAASHRGHERPSATTQCPVLRPEEVLADTHORSISPWRYVDTDDEDRYPQ 122
Db 93 pvalvssleaaashrgherpsattqcpvlrpeevleadtorsispswryrvdtdedrypq 152

Qy 123 KLAFACLCRCIDARTGRETAALNSVRLQSLVLRPPCSRDGSGGLPTPGAFAFHTEF 182
Db 153 klafaelcrlcridartgretaalnsvrlqslvlrrppcsrdgsglptpgafafhtef 212

QY 183 IHVPVGCVCVLPKRSV 197
 Db 213 ihvpvgctcvlprsv 227

RESULT 15

AAE08681
 ID AAE08681 standard; Protein; 227 AA.

XX AC AAE08681;

XX DT 15-NOV-2001 (first entry)

XX DE Human interleukin (IL)-17 like protein mutant (Leu47Val).

XX KW Human: interleukin; IL-17 like protein; rheumatic disease; gene therapy;
 KW multiple sclerosis; graft versus host disease; inflammatory disease;
 KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
 KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
 KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.

XX OS Homo sapiens.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Misc-difference 47 /note= "Wild-type Leu substituted with Val"

XX PN WO200159120-A2.

XX PD 16-AUG-2001.

XX PF 07-FEB-2001; 2001WO-US03916.

XX PR 08-FEB-2000; 2000US-0180864.

XX PR 27-NOV-2000; 2000US-0722920.

XX PA (AMGE-) AMGEN INC.

XX PI Jing S, Bass MB;

XX DR WPI; 2001-529841/58.

XX PT Novel interleukin-17 like polypeptides and nucleic acid molecules
 PT encoding them useful for diagnosis, prevention and treatment of
 PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
 PT rejection

XX PS Claim 18; Page -: 117pp; English.

XX CC The present invention relates to interleukin (IL)-17 like polypeptides
 CC and nucleic acids encoding them. IL-17 like protein is useful for
 CC identifying binding partners, agonists and antagonists which can be used
 CC for treating one or more diseases or disorders and for cloning IL-17
 CC like receptors, using an expression cloning strategy. Radiolabelled or
 CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
 CC identify a cell type or cell line or tissue that express IL-17 like
 CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
 CC affinity ligand to identify and isolate from an expression library the
 CC subset of cells which express the IL-17 like receptors on their surface.
 CC IL-17 like protein, agonist and antagonist are useful for treating acute
 CC and chronic inflammation such as rheumatic diseases, graft versus host
 CC disease and multiple sclerosis. IL-17 like antagonists are useful for
 CC treating and preventing inflammatory disease, autoimmune disease,
 CC allergies, asthma and organ or graft rejection in a patient and also
 CC for inhibiting T cell proliferation and/or activation, in vivo B cell
 CC proliferation or immunoglobulin secretion, and for blocking the effects
 CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
 CC gene therapy and for mapping the location of the IL-17 like gene and
 CC related genes on chromosomes, as hybridisation probes in diagnostic
 CC assays. Non-human animals in which the promoter for one or more of IL-17
 CC like protein is either activated or inactivated are useful for drug
 CC candidate screening. The present sequence is human IL-17 like

CC protein mutant (Leu47Val).
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
 CC (AAE08676), shown in figure 1A.

XX SQ Sequence 227 AA;

Query Match 98.8%; Score 1060; DB 22; Length 227;
 Best Local Similarity 99.5%; Pred. No. 1.5e-107;
 Matches 194; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 LLPCLLFTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPPLHLAGAKMGQAL 62

Db 33 llpgllflftwlhtcvahdpshlrgphshgtphcysaeelpgqapphllargakwgqal 92

QY 63 PVALVSSLEAASHRGRIERSATTQCPLRPPEVLEADTHQRSISPWRYRVDDEDRYPQ 122

Db 93 pvalvssleashaashrgriersattqcplrppeevleadtqrsispswryrvdtdedrypq 152

QY 123 KLAFACLCRCGCDARTGRTAALNSVRLQLSLVLRERRPCSRDGSGLPTPGAFAPHTF 182

Db 153 klafaelcrgcdartgretaalsvrlqlslvllrrpcsdrgsglptpgafafhtef 212

QY 183 IHVPVGCVCVLPKRSV 197

Db 213 ihvpvgctcvlprsv 227

RESULT 16

AAE08685
 ID AAE08685 standard; Protein; 227 AA.

XX AC AAE08685;

XX DT 15-NOV-2001 (first entry)

XX DE Human interleukin (IL)-17 like protein mutant (Glu110Asp).

XX KW Human: interleukin; IL-17 like protein; rheumatic disease; gene therapy;
 KW multiple sclerosis; graft versus host disease; inflammatory disease;
 KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
 KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
 KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.

XX OS Homo sapiens.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Misc-difference 110 /note= "Wild-type Glu substituted with Asp"

XX PN WO200159120-A2.

XX PD 16-AUG-2001.

XX PF 07-FEB-2001; 2001WO-US03916.

XX PR 08-FEB-2000; 2000US-0180864.

XX PR 27-NOV-2000; 2000US-0722920.

XX PA (AMGE-) AMGEN INC.

XX PI Jing S, Bass MB;

XX DR WPI; 2001-529841/58.

XX PT Novel interleukin-17 like polypeptides and nucleic acid molecules
 PT encoding them useful for diagnosis, prevention and treatment of
 PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
 PT rejection

XX PS Claim 19; Page -: 117pp; English.

XX The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Glul10Asp).
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.

XX Sequence 227 AA;

Query Match 98.8%; Score 1060; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 1.5e-107;
Matches 194; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 3 LLPGLLFTLWHTCLAHHDPSLRGPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
Db 33 LLPGLLFTLWHTCLAHHDPSLRGPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 92
QY 63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHQRSIPWRYRVDTEDRYPQ 122
Db 93 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHQRSIPWRYRVDTEDRYPQ 152
QY 123 KLAFACLCRCGIDARTGRETAAALNSVRLQLSLVLRPPCRSDGSLPTPGAFATFTEF 182
Db 153 klafaelcrgcidartgretaaalnsrvllqslvlrrpcsrldgslptpgafafhtef 212
QY 183 IHVPVGTCTVLPRSV 197
Db 213 ihvpvgctcvlprsv 227

RESULT 17

AAE08684
ID AAE08684 standard; Protein: 227 AA.

XX AC AAE08684;

XX AC AAE08684;

XX AC AAE08684;

XX 15-NOV-2001 (first entry)

XX Human Interleukin (IL)-17 like protein mutant (Leu47Phe).

XX Human; Interleukin; IL-17 like protein; rheumatic disease; gene therapy;

XX multiple sclerosis; graft versus host disease; inflammatory disease;

XX asthma; autoimmune disease; allergy; graft rejection; bone destruction;

XX drug screening; antiinflammatory; immunosuppressive; antidiabetic;

XX neuroprotective; antirheumatic; antiallergic; mutant; mutein.

XX Homo sapiens.

FT Misc-difference 47 /note= "Wild-type Leu substituted with Phe"
FT FT
PN WO200159120-A2.
XX 16-AUG-2001.
PD 07-FEB-2001; 2001WO-US03916.
XX 08-FEB-2000; 2000US-0180864.
XX 27-NOV-2000; 2000US-0722920.
PR (AMGE-) AMGEN INC.
XX Jing S, Bass MB;
PI WPI; 2001-529841/58.
DR Novel interleukin-17 like polypeptides and nucleic acid molecules
XX encoding them useful for diagnosis, prevention and treatment of
PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT rejection
XX Claim 18; Page -: 117pp; English.

XX The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Leu47Phe).
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.

XX Sequence 227 AA;

Query Match 98.7%; Score 1059; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 1.5e-107;
Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 LLPGLLFTLWHTCLAHHDPSLRGPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
Db 33 LLPGLLFTLWHTCLAHHDPSLRGPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 92
QY 63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHQRSIPWRYRVDTEDRYPQ 122
Db 93 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHQRSIPWRYRVDTEDRYPQ 152
QY 123 KLAFACLCRCGIDARTGRETAAALNSVRLQLSLVLRPPCRSDGSLPTPGAFATFTEF 182
Db 153 klafaelcrgcidartgretaaalnsrvllqslvlrrpcsrldgslptpgafafhtef 212
QY 183 IHVPVGTCTVLPRSV 197

Db 213 ihvpvgctcvlprsv 227

RESULT 18

AAE08679
ID AAE08687 standard; Protein: 227 AA.

AC AAE08687;

DT 15-NOV-2001 (first entry)

XX Human interleukin (IL)-17 like protein mutant (Tyr141Phe).

DE Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antisthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; muten.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FH Misc-difference 141

FT /note= "Wild-type Tyr substituted with Phe"

FT XX

PN WO200159120-A2.

XX 16-AUG-2001.

PD 07-FEB-2001; 2001WO-US03916.

XX 08-FEB-2000; 2000US-0180864.

PR 27-NOV-2000; 2000US-0722920.

XX (AMGE-) AMGEN INC.

PA Jing S, Bass MB;

XX WPI; 2001-529841/58.

DR Novel interleukin-17 like polypeptides and nucleic acid molecules

XX encoding them useful for diagnosis, prevention and treatment of

PT inflammatory, autoimmune disease, allergies, asthma and organ or graft

PT rejection

XX Claim 20; Page -: 117pp; English.

PS The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Tyr141Phe).

CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.

XX SQ Sequence 227 AA;

Query Match 98.7%; Score 1059; DB 22; Length 227;

Best Local Similarity 99.5%; Pred. No. 1.9e-107;

Matches 194; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 LLPGLFLTWLHTCLAHHDPSLGRHSHGTHPCYSAEELPLGQAPPHLLARGAKWGQAL 62

Db 33 lllpgllflftwlhtclahhdpslgrhshgthpcysaeelpgqapphllargakwgqal 92

QY 63 PVALVSSLEAASRGRRHERPSATQCPVLRPEEVLEADTHQRTSPWRYRVDTDDEYPO 122

Db 93 pvalvssleasrgrhrherpsatqcpvlrpeevleadtqrsisprwrvdtdedrypq 152

QY 123 KLAFAECLRCGICDARTGRETAALNSVRLQLSLVLRRRPCSRDGGSLPTPGAFARHTEF 182

Db 153 klafaeclrcgicdartgreetaalnsvrlqlslvlrrrrpcsrddgslptpgafafhtef 212

QY 183 IHVPVGCTCVLPRSV 197

Db 213 ihvpvgctcvlprsv 227

RESULT 19

AAE08679

ID AAE08679 standard; Protein: 227 AA.

AC AAE08679;

DT 15-NOV-2001 (first entry)

XX Human interleukin (IL)-17 like protein mutant (Leu47Nle).

XX Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;

XX multiple sclerosis; graft versus host disease; inflammatory disease;

XX asthma; autoimmune disease; allergy; graft rejection; bone destruction;

XX drug screening; antiinflammatory; immunosuppressive; antisthmatic;

XX neuroprotective; antirheumatic; antiallergic; mutant; muten.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FH Misc-difference 47

FT /label= Nle

FT /note= "Wild-type Leu substituted with Nle"

XX WO200159120-A2.

XX 16-AUG-2001.

XX 07-FEB-2001; 2001WO-US03916.

PR 08-FEB-2000; 2000US-0180864.

PR 27-NOV-2000; 2000US-0722920.

XX (AMGE-) AMGEN INC.

XX Jing S, Bass MB;

XX WPI; 2001-529841/58.

XX Novel interleukin-17 like polypeptides and nucleic acid molecules

XX encoding them useful for diagnosis, prevention and treatment of

XX inflammatory, autoimmune disease, allergies, asthma and organ or graft

XX rejection

XX Claim 18; Page -: 117pp; English.

XX The present invention relates to interleukin (IL)-17 like polypeptides
 CC and nucleic acids encoding them. IL-17 like protein is useful for
 CC identifying binding partners, agonists and antagonists which can be used
 CC for treating one or more diseases or disorders and for cloning IL-17
 CC like receptors, using an expression cloning strategy. Radiolabelled or
 CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
 CC identify a cell type or cell line or tissue that express IL-17 like
 CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
 CC affinity ligand to identify and isolate from an expression library the
 CC subset of cells which express the IL-17 like receptors on their surface.
 CC IL-17 like protein, agonist and antagonist are useful for treating acute
 CC and chronic inflammation such as rheumatic diseases, graft versus host
 CC disease and multiple sclerosis. IL-17 like antagonists are useful for
 CC treating and preventing inflammatory disease, autoimmune disease,
 CC allergies, asthma and organ or graft rejection in a patient and also
 CC for inhibiting T cell proliferation and/or activation, in vivo B cell
 CC proliferation or immunoglobulin secretion, and for blocking the effects
 CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
 CC gene therapy and for mapping the location of the IL-17 like gene and
 CC related genes on chromosomes, as hybridisation probes in diagnostic
 CC assays. Non-human animals in which the promoter for one or more of IL-17
 CC like protein is either activated or inactivated are useful for drug
 CC candidate screening. The present sequence is human IL-17 like
 CC protein mutant (Leu47Nle).
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
 CC (AAE08676), shown in figure 1A.

XX Sequence 227 AA;

Query Match 98.6%; Score 1058; DB 22; Length 227;
 Best Local Similarity 99.5%; Pred. No. 2.4e-107;
 Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 3 LLPGLLELTWLTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
 .Db 33 LLPGLLFTWLTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 92
 Qy 63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHQSRISPMWRVDTDEDYPPQ 122
 Db 93 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHQSRISPMWRVDTDEDYPPQ 152
 Qy 123 KLAFACLCRCGIDARTGRETAAINSVRLQLSLLVLRPPCRDGSGLPTPGAFATFTEF 182
 Db 153 klafaelcrgcidartgretaaalnsrllqslvlrrpcsrldgsglptpgafafatf 212
 Qy 183 IHVPVGCTCVLPRSV 197
 Db 213 ihvpvgctcvlprsv 227

RESULT 20

AAE08683
 ID AAE08683 standard; Protein; 227 AA.

XX AAE08683;

XX 15-NOV-2001 (first entry)

XX Human interleukin (IL)-17 like protein mutant (Leu47Ala).

XX Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
 KW multiple sclerosis; graft versus host disease; inflammatory disease;
 KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
 KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
 KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.

XX Homo sapiens.
 OS Synthetic.

XX Key Location/Qualifiers

FT Misc-difference 47 /note= "Wild-type Leu substituted with Ala"
 FT FT
 XX WO200159120-A2.
 PN 16-AUG-2001.
 XX 07-FEB-2001; 2001WO-US03916.
 PD 08-FEB-2000; 2000US-0180864.
 PF 27-NOV-2000; 2000US-0722920.
 XX (AMGE-) AMGEN INC.
 PA Jing S, Bass MB;
 PI WPI; 2001-529841/58.
 DR Novel interleukin-17 like polypeptides and nucleic acid molecules
 XX encoding them useful for diagnosis, prevention and treatment of
 PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
 PT rejection.
 XX Claim 18; Page -: 117pp; English.
 PS The present invention relates to interleukin (IL)-17 like polypeptides
 CC and nucleic acids encoding them. IL-17 like protein is useful for
 CC identifying binding partners, agonists and antagonists which can be used
 CC for treating one or more diseases or disorders and for cloning IL-17
 CC like receptors, using an expression cloning strategy. Radiolabelled or
 CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
 CC identify a cell type or cell line or tissue that express IL-17 like
 CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
 CC affinity ligand to identify and isolate from an expression library the
 CC subset of cells which express the IL-17 like receptors on their surface.
 CC IL-17 like protein, agonist and antagonist are useful for treating acute
 CC and chronic inflammation such as rheumatic diseases, graft versus host
 CC disease and multiple sclerosis. IL-17 like antagonists are useful for
 CC treating and preventing inflammatory disease, autoimmune disease,
 CC allergies, asthma and organ or graft rejection in a patient and also
 CC for inhibiting T cell proliferation and/or activation, in vivo B cell
 CC proliferation or immunoglobulin secretion, and for blocking the effects
 CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
 CC gene therapy and for mapping the location of the IL-17 like gene and
 CC related genes on chromosomes, as hybridisation probes in diagnostic
 CC assays. Non-human animals in which the promoter for one or more of IL-17
 CC like protein is either activated or inactivated are useful for drug
 CC candidate screening. The present sequence is human IL-17 like
 CC protein mutant (Leu47Ala).
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
 CC (AAE08676), shown in figure 1A.

XX Sequence 227 AA;

Query Match 98.6%; Score 1058; DB 22; Length 227;
 Best Local Similarity 99.5%; Pred. No. 2.4e-107;
 Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 3 LLPGLLELTWLTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
 Db 33 LLPGLLFTWLTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 92
 Qy 63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHQSRISPMWRVDTDEDYPPQ 122
 Db 93 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHQSRISPMWRVDTDEDYPPQ 152
 Qy 123 KLAFACLCRCGIDARTGRETAAINSVRLQLSLLVLRPPCRDGSGLPTPGAFATFTEF 182
 Db 153 klafaelcrgcidartgretaaalnsrllqslvlrrpcsrldgsglptpgafafatf 212
 Qy 183 IHVPVGCTCVLPRSV 197

Db 213 ihvpvgctcplprsv 227

|||||

RESULT 21
AAE08686
ID AAE08686 standard; Protein; 227 AA.

XX AAE08686;

XX 15-NOV-2001 (first entry)

XX Human interleukin (IL)-17 like protein mutant (Tyr141Trp).

XX Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
XX multiple sclerosis; graft versus host disease; inflammatory disease;
XX asthma; autoimmune disease; allergy; graft rejection; bone destruction;
XX drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
XX neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX Homo sapiens.
XX Synthetic.

XX Key Location/Qualifiers

XX Misc-difference 141 /note= "Wild-type Tyr substituted with Trp"

XX WO200159120-A2.

XX 16-AUG-2001.

XX 07-FEB-2001; 2001WO-US03916.

XX 08-FEB-2000; 2000US-0180864.

XX 27-NOV-2000; 2000US-0722920.

XX (AMGE-) AMGEN INC.

XX Jing S, Bass MB;

XX WPI; 2001-529841/58.

XX Novel interleukin-17 like polypeptides and nucleic acid molecules
XX encoding them useful for diagnosis, prevention and treatment of
XX inflammatory, autoimmune disease, allergies, asthma and organ or graft
XX rejection

XX Claim 20; Page -: 117pp; English.

XX The present invention relates to interleukin (IL)-17 like polypeptides
XX and nucleic acids encoding them. IL-17 like protein is useful for
XX identifying binding partners, agonists and antagonists which can be used
XX for treating one or more diseases or disorders and for cloning IL-17
XX like receptors, using an expression cloning strategy. Radiolabelled or
XX affinity/activity-tagged IL-17 proteins are useful in binding assays to
XX identify a cell type or cell line or tissue that express IL-17 like
XX receptors. A radiolabelled or tagged IL-17 like protein is useful as an
XX affinity ligand to identify and isolate from an expression library the
XX subset of cells which express the IL-17 like receptors on their surface.
XX IL-17 like protein, agonist and antagonist are useful for treating acute
XX and chronic inflammation such as rheumatic diseases, graft versus host
XX disease and multiple sclerosis. IL-17 like antagonists are useful for
XX treating and preventing inflammatory disease, autoimmune disease,
XX allergies, asthma and organ or graft rejection in a patient and also
XX for inhibiting T cell proliferation and/or activation, in vivo B cell
XX proliferation or immunoglobulin secretion, and for blocking the effects
XX of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
XX gene therapy and for mapping the location of the IL-17 like gene and
XX related genes on chromosomes, as hybridisation probes in diagnostic
XX assays. Non-human animals in which the promoter for one or more of IL-17
XX like protein is either activated or inactivated are useful for drug
XX candidate screening. The present sequence is human IL-17 like
XX protein mutant (Tyr141Trp).

CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.

XX SQ Sequence 227 AA;

Query Match 98.6%; Score 1058; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 2.4e-107;
Matches 194; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 LLPGLLELTWLTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLARAKWGQAL 62
Db 33 llpgllfitwlhtclahdpslrgrhphshgtphcysaeelpgqapphlargakwgqal 92

QY 63 PVALVSSLEAAASHRGHRRPESATTQCPVLRPEEVLADTHQRSISPWRYRVDDEDRYPQ 122
Db 93 pvalvssleashrgrhrrpsattqcpvlrpeevleadtqrsisprwrvrvtddedrypq 152

QY 123 KLAFACLCRCIDARTGRTAALNSVRLQLSLVLRRCRDSRGSLPTPGAFAFHTEF 182
Db 153 klafaeclrcgcidartgretaalnsrvllqlslvlrrpcsrdsrgslptpgafafhtef 212

QY 183 IHVPVGCTCPLPRSV 197

Db 213 ihvpvgctcplprsv 227

RESULT 22

AAE08690
ID AAE08690 standard; Protein; 227 AA.

XX AAE08690;

XX 15-NOV-2001 (first entry)

XX Human interleukin (IL)-17 like protein mutant (Pro151Ala).

XX Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
XX multiple sclerosis; graft versus host disease; inflammatory disease;
XX asthma; autoimmune disease; allergy; graft rejection; bone destruction;
XX drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
XX neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX Homo sapiens.
XX Synthetic.

XX Key Location/Qualifiers

XX Misc-difference 151 /note= "Wild-type Pro substituted with Ala"

XX WO200159120-A2.

XX 16-AUG-2001.

XX 07-FEB-2001; 2001WO-US03916.

XX 08-FEB-2000; 2000US-0180864.

XX 27-NOV-2000; 2000US-0722920.

XX (AMGE-) AMGEN INC.

XX Jing S, Bass MB;

XX WPI; 2001-529841/58.

XX Novel interleukin-17 like polypeptides and nucleic acid molecules
XX encoding them useful for diagnosis, prevention and treatment of
XX inflammatory, autoimmune disease, allergies, asthma and organ or graft
XX rejection

XX Claim 21; Page -: 117pp; English.

CC The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Pro151Ala).
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.

XX Sequence 227 AA;

Query Match 98.3%; Score 1055; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 5.2e-107;
Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3 LLPGLLFTLWLTCLAHHDPSLRGPHSHGTPHCYSAEELPLGOAPPHELLARGAKWGQAL 62
DB 33 LLPGLLFTLWLTCLAHHDPSLRGPHSHGTPHCYSAEELPLGOAPPHELLARGAKWGQAL 92
QY 63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVEADTHQSRISPMWRYRVDDEDRYQ 122
DB 93 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVEADTHQSRISPMWRYRVDDEDRYQ 152
QY 123 KLAFACELRCGCDIARTGRETAAALNSVRLLOSLLVLRPPCSRDCSGLPTPGAFHFTEF 182
DB 153 klafaelcrgcdartgretaaalnsrvllqslvlrrpcsrddsgslptpgafafhtef 212
QY 183 IHVPVGGTCVLPVRSV 197
DB 213 ihvpvgctcvlprsv 227

RESULT 23

AAE08688

ID AAE08688 standard; Protein; 227 AA.

XX AAE08688;

XX AAE08688;

DF 15-NOV-2001 (first entry)

DE Human interleukin (IL)-17 like protein mutant (Tyr141Thr).

KW Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutagen.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FX Misc-difference 141

FT

FT /note= "Wild-type Tyr substituted with Thr"
XX
XX WO200159120-A2.

XX 16-AUG-2001.

XX 07-FEB-2001; 2001WO-US03916.

XX 08-FEB-2000; 2000US-0180864.

XX 27-NOV-2000; 2000US-0722920.

XX (AMGE-) AMGEN INC.

XX Jing S, Bass MB;

XX WPI; 2001-529841/58.

XX Novel interleukin-17 like polypeptides and nucleic acid molecules
XX encoding them useful for diagnosis, prevention and treatment of
XX inflammatory, autoimmune disease, allergies, asthma and organ or graft
XX rejection .
XX Claim 20; Page -; 117pp; English.

XX The present invention relates to interleukin (IL)-17 like polypeptides
XX and nucleic acids encoding them. IL-17 like protein is useful for
XX identifying binding partners, agonists and antagonists which can be used
XX for treating one or more diseases or disorders and for cloning IL-17
XX like receptors, using an expression cloning strategy. Radiolabelled or
XX affinity/activity-tagged IL-17 proteins are useful in binding assays to
XX identify a cell type or cell line or tissue that express IL-17 like
XX receptors. A radiolabelled or tagged IL-17 like protein is useful as an
XX affinity ligand to identify and isolate from an expression library the
XX subset of cells which express the IL-17 like receptors on their surface.
XX IL-17 like protein, agonist and antagonist are useful for treating acute
XX and chronic inflammation such as rheumatic diseases, graft versus host
XX disease and multiple sclerosis. IL-17 like antagonists are useful for
XX treating and preventing inflammatory disease, autoimmune disease,
XX allergies, asthma and organ or graft rejection in a patient and also
XX for inhibiting T cell proliferation and/or activation, in vivo B cell
XX proliferation or immunoglobulin secretion, and for blocking the effects
XX of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
XX gene therapy and for mapping the location of the IL-17 like gene and
XX related genes on chromosomes, as hybridisation probes in diagnostic
XX assays. Non-human animals in which the promoter for one or more of IL-17
XX like protein is either activated or inactivated are useful for drug
XX candidate screening. The present sequence is human IL-17 like
XX protein mutant (Tyr141Thr).
XX Note: The present sequence is not shown in the specification, but is
XX derived from the human IL-17 like protein referred to as SEQ ID NO:2
XX (AAE08676), shown in figure 1A.

XX Sequence 227 AA;

Query Match 98.2%; Score 1054; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 6.7e-107;
Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 LLPGLLFTLWLTCLAHHDPSLRGPHSHGTPHCYSAEELPLGOAPPHELLARGAKWGQAL 62

DB 33 LLPGLLFTLWLTCLAHHDPSLRGPHSHGTPHCYSAEELPLGOAPPHELLARGAKWGQAL 92

QY 63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVEADTHQSRISPMWRYRVDDEDRYQ 122

DB 93 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVEADTHQSRISPMWRYRVDDEDRYQ 152

QY 123 KLAFACELRCGCDIARTGRETAAALNSVRLLOSLLVLRPPCSRDCSGLPTPGAFHFTEF 182

DB 153 klafaelcrgcdartgretaaalnsrvllqslvlrrpcsrddsgslptpgafafhtef 212

QY 183 IHVPVGGTCVLPVRSV 197

DB 213 ihvpvgctcvlprsv 227

Db 213 ihvpvgctcvlprsv 227

RESULT 24
AAE08689
ID AAE08689 standard; Protein; 227 AA.
AC AAE08689;
XX
XX 15-NOV-2001 (first entry)
XX Human interleukin (IL)-17 like protein mutant (Tyr141Ser).
XX Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FT Misc-difference 141 /note= "Wild-type Tyr substituted with Ser"
FT
XX
XX WO200159120-A2.
XX
XX PD 16-AUG-2001.
XX
XX PF 07-FEB-2001; 2001WO-US03916.
XX
XX PR 08-FEB-2000; 2000US-0180864.
XX PR 27-NOV-2000; 2000US-0722920.
XX
XX PA (AMGE-) AMGEN INC.
XX
XX PI Jing S, Bass MB;
XX WPI; 2001-529841/58.
XX
XX Novel interleukin-17 like polypeptides and nucleic acid molecules
PT encoding them useful for diagnosis, prevention and treatment of
PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT rejection
XX
XX Claim 20; Page -: 117pp; English.

The present invention relates to interleukin (IL)-17 like polypeptides and nucleic acids encoding them. IL-17 like protein is useful for identifying binding partners, agonists and antagonists which can be used for treating one or more diseases or disorders and for cloning IL-17 like receptors, using an expression cloning strategy. Radiolabelled or affinity/activity-tagged IL-17 proteins are useful in binding assays to identify a cell type or cell line or tissue that express IL-17 like receptors. A radiolabelled or tagged IL-17 like protein is useful as an affinity ligand to identify and isolate from an expression library the subset of cells which express the IL-17 like receptors on their surface. IL-17 like protein, agonist and antagonist are useful for treating acute and chronic inflammation such as rheumatic diseases, graft versus host disease and multiple sclerosis. IL-17 like antagonists are useful for treating and preventing inflammatory disease, autoimmune disease, allergies, asthma and organ or graft rejection in a patient and also for inhibiting T cell proliferation and/or activation, in vivo B cell proliferation or immunoglobulin secretion, and for blocking the effects of IL-17 in inducing bone destruction. IL-17 like molecule is useful in gene therapy and for mapping the location of the IL-17 like gene and related genes on chromosomes, as hybridisation probes in diagnostic assays. Non-human animals in which the promoter for one or more of IL-17 like protein is either activated or inactivated are useful for drug candidate screening. The present sequence is human IL-17 like protein mutant (Tyr141Ser).

Note: The present sequence is not shown in the specification, but is

CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.
XX
SQ Sequence 227 AA;

Query Match 98.2%; Score 1054; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 6,7e-107;
Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 LLPLGLFLTWLHTCLAHHDPSLRGPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGOAL 62
DB 33 lllpqlfltlwhtclahhdpslrghphshgtphcysaeelpgqapphllargakwqgal 92
QY 63 PVALVSSLEAAASHRGRIHERPSATTQCPVLRPEEVLADTHQRSISPMWRYRVDDEDRYPO 122
DB 93 pvalvssleaaashrgriherpsattqcpvlrpeevleadthqrsispmwrsrvdtedrypq 152
QY 123 KLAFAECLRCGICDARTGRETAALNSVRLQSLVLRRLRRPCSRDGSGLPTGPAFAHTEF 182
DB 153 klafaeclrcgicdartgreetaalnsvrlqslvlrrrrpcsdrgsglptpgafafhtef 212
QY 183 IHVPVGCTCVLPRSV 197
DB 213 ihvpvgctcvlprsv 227

RESULT 25
AAE08691
ID AAE08691 standard; Protein; 227 AA.
XX
XX AC AAE08691;
XX
XX DT 15-NOV-2001 (first entry)
XX
XX DE Human interleukin (IL)-17 like protein mutant (Pro151Gly).
XX
XX KW Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX Key Location/Qualifiers
FT Misc-difference 151 /note= "Wild-type Pro substituted with Gly"
FT
XX
XX PN WO200159120-A2.
XX
XX PD 16-AUG-2001.
XX
XX PF 07-FEB-2001; 2001WO-US03916.
XX
XX PR 08-FEB-2000; 2000US-0180864.
XX PR 27-NOV-2000; 2000US-0722920.
XX
XX PA (AMGE-) AMGEN INC.
XX
XX PI Jing S, Bass MB;
XX WPI; 2001-529841/58.
XX
XX Novel interleukin-17 like polypeptides and nucleic acid molecules
PT encoding them useful for diagnosis, prevention and treatment of
PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT rejection
XX
XX PS Claim 21; Page -: 117pp; English.
XX
XX CC The present invention relates to interleukin (IL)-17 like polypeptides

CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (ProJ51Gly).
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.
XX
SQ Sequence 227 AA;

Query Match 98.2%; Score 1054; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 6.7e-107;
Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3 LLPGLFLTLWLTCLAHDDPSLRGHPHSHGTPHCYSAEPLPGQAPPHLLARGAKWGQAL 62
Db 33 lllpglfltlwltclahddpslrghphshgtpchysaeelpgqapphlargakwgqal 92
Qy 63 PVALVSSLEAASHRGHRPERSATTQCPVLRPEEVLAEADTHORSISPWRYVDTDEDYYPQ 122
Db 93 pvalvssleaashrghrpersattqcpvlrpeevleadthorsispwryvdtdegyq 152
Qy 123 KLAFACLCRCGIDARTGRETAAALNSVRLQSLVLRPPCSRDGSLPTGCAFAFHTEF 182
Db 153 klafaelcrgcidartgretaalnsrvllqslvlrrpcsdrgslptpgafafhtef 212
Qy 183 IHVPVGCCTCVLPSPV 197
Db 213 ihvpvgctcvlpsv 227

RESULT 26

AAE08693

ID AAE08693 standard; Protein; 227 AA.

XX

AC AAE08693;

XX

DT 15-NOV-2001 (first entry)

XX

DE Human interleukin (IL)-17 like protein mutant (Cys159Ala).

XX

KW Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.

OS Homo sapiens.

OS Synthetic.

XX

FH Key Location/Qualifiers

XX

FT Misc-difference 159 /note= "wild-type Cys substituted with Ala"

XX

XX WO200159120-A2.
PN 16-AUG-2001.
PD 07-FEB-2001; 2001WO-US03916.
PF 08-FEB-2000; 2000US-0180864.
PR 27-NOV-2000; 2000US-0722920.
PX (AMGE-) AMGEN INC.
PA
PI Jing S, Bass MB;
XX WPI; 2001-529841/58.
DR
XX Novel interleukin-17 like polypeptides and nucleic acid molecules
PT encoding them useful for diagnosis, prevention and treatment of
PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT rejection
XX
PS Claim 22; Page -: 117pp; English.
XX
CC The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease, also
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Cys159Ala).
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.
XX
SQ Sequence 227 AA;

Query Match 98.2%; Score 1054; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 6.7e-107;
Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3 LLPGLFLTLWLTCLAHDDPSLRGHPHSHGTPHCYSAEPLPGQAPPHLLARGAKWGQAL 62
Db 33 lllpglfltlwltclahddpslrghphshgtpchysaeelpgqapphlargakwgqal 92
Qy 63 PVALVSSLEAASHRGHRPERSATTQCPVLRPEEVLAEADTHORSISPWRYVDTDEDYYPQ 122
Db 93 pvalvssleaashrghrpersattqcpvlrpeevleadthorsispwryvdtdegyq 152
Qy 123 KLAFACLCRCGIDARTGRETAAALNSVRLQSLVLRPPCSRDGSLPTGCAFAFHTEF 182
Db 153 klafaelcrgcidartgretaalnsrvllqslvlrrpcsdrgslptpgafafhtef 212
Qy 183 IHVPVGCCTCVLPSPV 197
Db 213 ihvpvgctcvlpsv 227

CC	(AAE08676), shown in figure 1A.
XX	
SQ	Sequence 227 AA;
Query Match	98.2%; Score 1054; DB 22; Length 227;
Best Local Similarity	99.5%; Pred. No. 6.7e-107;
Matches 194; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
QY	3 LLPGLLFTWLHTCLAHHDPSLRGHPHSHGTTPHCYSAEELPLGOAPPHLLARGAKWGQAL 62
Db	33 ilpgllftwlhtclahhdpslrghphshgtpchysaeelpgqapphlilargakwgqal 92
QY	63 PVALVSSLEAAASHRGRHERPSATTQCPLRPPEEVLEADTHORSTSPWRYRVDDDEDPYQ 122
Db	93 pvalvssleaaashrgrherpsattqcplrppeevleadthqrsispwryrvdtdedryp 152
QY	123 KLAFAECLRCGDARTGRETAALNSVRLLQSLAVLRPRCSRDSGLPTPGAFARHTEF 182
Db	153 klafaeclarcgdartgretaalnsvrllqlslvlrrpcsrdsrglptpgafaftef 212
QY	183 IHVPVGCTCVLP RSV 197
Db	213 ihvpvgctcvlp rsv 227
RESULT 28	
AAE08697	
ID	AAE08697 standard; Protein; 227 AA.
XX	
AC	AAE08697;
XX	
DT	15-NOV-2001 (first entry)
XX	
DE	Human interleukin (IL)-17 like protein mutant (Cys164Ala).
XX	
KW	Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy; multiple sclerosis; graft versus host disease; inflammatory disease; aschma; autoimmune disease; allergy; graft rejection; bone destruction; drug screening; antiinflammatory; immunosuppressive; antiasthmatic; neuroprotective; antirheumatic; antiallergic; mutant; mutein.
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	Misc-difference 164
ET	/note= "Wild-type Cys substituted with Ala"
XX	
PN	WO200159120-A2.
XX	
PD	16-AUG-2001.
XX	
PF	07-FEB-2001; 2001WO-US03916.
XX	
PR	08-FEB-2000; 2000US-0180864.
XX	
PR	27-NOV-2000; 2000US-0722920.
XX	
PA	(AMGE-) AMGEN INC.
XX	
PI	Jing S, Bass MB;
XX	
DR	WPI; 2001-529841/58.
XX	
PT	Novel interleukin-17 like polypeptides and nucleic acid molecules encoding them useful for diagnosis, prevention and treatment of inflammatory, autoimmune disease, allergies, asthma and organ or graft rejection
XX	
PS	Claim 24; Page -; 117pp; English.
XX	
CC	The present invention relates to interleukin (IL)-17 like polypeptides and nucleic acids encoding them. IL-17 like protein is useful for
CC	

RESULT	27	
AAE08695		
ID	AAE08695	standard; Protein; 227 AA.
XX	AC	
XX	AAE08695;	
XX		
XX	15-NOV-2001	(first entry)
XX		
XX	Human interleukin (IL)-17	like protein mutant (Cys161Ala).
XX		
XX	Human; interleukin; IL-17	like protein; rheumatic disease; gene therapy;
KW	multiple sclerosis; graft	versus host disease; inflammatory disease;
KW	asthma; autoimmune disease;	allergy; graft rejection; bone destruction;
KW	drug screening; antiinflammatory;	immunosuppressive; antithumatic;
KW	neuroprotective; antirheumatic;	antiallergic; mutant; mutein.
XX		
XX	Homo sapiens.	
OS	Synthetic.	
XX		
XX	Key	Location/Qualifiers
FH	Misc-difference 161	
FT	/note=	"Wild-type Cys substituted with Ala"
FT		
XX	W0200159120-A2.	
XX		
XX	16-AUG-2001.	
XX		
XX	07-FEB-2001;	2001WO-US03916.
XX		
XX	08-FEB-2000;	2000US-0180864.
PR	27-NOV-2000;	2000US-0722920.
XX		
XX	(AMGE-)	AMGEN INC.
XX		
XX	Jing S,	Bass MB;
PI		
XX		
XX	WPI;	2001-529841/58.
DR		
XX		
XX	Novel interleukin-17	like polypeptides and nucleic acid molecules
PT	encoding them useful	for diagnosis, prevention and treatment of
PT	inflammatory, autoimmune	disease, allergies, asthma and organ or graft
PT	rejection	
XX		
XX	Claim 23;	Page -: 117pp; English.
XX		
XX	The present invention	relates to interleukin (IL)-17 like polypeptides
CC	and nucleic acids	encoding them. IL-17 like protein is useful for
CC	identifying binding	partners, agonists and antagonists which can be used
CC	for treating one	or more diseases or disorders and for cloning IL-17
CC	like receptors, using	an expression cloning strategy. Radiolabelled or
CC	affinity/activity-tagged	IL-17 proteins are useful in binding assays to
CC	identify a cell type	or cell line or tissue that express IL-17 like
CC	receptors. A radiolabelled	or tagged IL-17 like protein is useful as an
CC	affinity ligand to	identify and isolate from an expression library the
CC	subset of cells which	express the IL-17 like receptors on their surface.
CC	IL-17 like protein,	agonist and antagonist are useful for treating acute
CC	and chronic inflammation	such as rheumatic diseases, graft versus host
CC	disease and multiple	sclerosis. IL-17 like antagonists are useful for
CC	treating and preventing	inflammatory disease, autoimmune disease,
CC	allergies, asthma	and organ or graft rejection in a patient and also
CC	for inhibiting T cell	proliferation and/or activation, in vivo B cell
CC	proliferation or	immunoglobulin secretion, and for blocking the effects
CC	of IL-17 in inducing	bone destruction. IL-17 like molecule is useful in
CC	gene therapy and for	mapping the location of the IL-17 like gene and
CC	related genes on	chromosomes, as hybridisation probes in diagnostic
CC	assays. Non-human	animals in which the promoter for one or more of IL-17
CC	like protein is	either activated or inactivated are useful for drug
CC	candidate screening.	The present sequence is human IL-17 like
CC	protein mutant (Cys161Ala).	
CC	Note: The present	sequence is not shown in the specification, but is
CC	derived from the	human IL-17 like protein referred to as SEQ ID No:2

RESULT 30
 AAE08701
 ID AAE08701 standard; Protein; 227 AA.
 AC AAE08701;
 XX 15-NOV-2001 (first entry)
 DT Human interleukin (IL)-17 like protein mutant (Cys219Ala).
 DE Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
 XX multiple sclerosis; graft versus host disease; inflammatory disease;
 KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
 KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
 KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 219 /note= "Wild-type Cys substituted with Ala"
 FT
 XX WO200159120-A2.
 XX 16-AUG-2001.
 XX 07-FEB-2001; 2001WO-US03916.
 XX 08-FEB-2000; 2000US-0180864.
 PR 27-NOV-2000; 2000US-0722920.
 XX (AMGE-) AMGEN INC.
 XX
 XX Jing S, Bass MB;
 DR WPI; 2001-529841/58.
 XX Novel interleukin-17 like polypeptides and nucleic acid molecules
 PT encoding them useful for diagnosis, prevention and treatment of
 PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
 PT rejection -
 XX
 Claim 26; Page -: 117pp; English.
 XX The present invention relates to interleukin (IL)-17 like polypeptides
 CC and nucleic acids encoding them. IL-17 like protein is useful for
 CC identifying binding partners, agonists and antagonists which can be used
 CC for treating one or more diseases or disorders and for cloning IL-17
 CC like receptors, using an expression cloning strategy. Radiolabelled or
 CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
 CC identify a cell type or cell line or tissue that express IL-17 like
 CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
 CC affinity ligand to identify and isolate from an expression library the
 CC subset of cells which express the IL-17 like receptors on their surface.
 CC IL-17 like protein, agonist and antagonist are useful for treating acute
 CC and chronic inflammation such as rheumatic diseases, graft versus host
 CC disease and multiple sclerosis. IL-17 like antagonists are useful for
 CC treating and preventing inflammatory disease, autoimmune disease,
 CC allergies, asthma and organ or graft rejection in a patient and also
 CC for inhibiting T cell proliferation and/or activation, in vivo B cell
 CC proliferation or immunoglobulin secretion, and for blocking the effects
 CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
 CC gene therapy and for mapping the location of the IL-17 like gene and
 CC related genes on chromosomes, as hybridisation probes in diagnostic
 CC assays. Non-human animals in which the promoter for one or more of IL-17
 CC like protein is either activated or inactivated are useful for drug
 CC candidate screening. The present sequence is human IL-17 like
 CC protein mutant (Cys219Ala).
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
 CC (AAE08676), shown in figure 1A.

XX SQ Sequence 227 AA;
 Query Match 98.2%; Score 1054; DB 22; Length 227;
 Best Local Similarity 99.5%; Pred. No. 6.7e-107;
 Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3 LLPGLLEFLTWLHTCLAHDPSSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
 DB 33 LLPGLLFTLWHTCLAHDPSSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 92
 QY 63 PVALVSSLEAASHRGHRERPSATTQCPLRPEEVLEADTHQRSISPWRYRVDTDEDYPO 122
 DB 93 PVALVSSLEAASHRGHRERPSATTQCPLRPEEVLEADTHQRSISPWRYRVDTDEDYPO 152
 QY 123 KLAFACGLRCGCDARTGRETAAALNSVRLQSLILVLRRCRSDGSLPTGPAFAFHTF 182
 DB 153 KLAFACGLRCGCDARTGRETAAALNSVRLQSLILVLRRCRSDGSLPTGPAFAFHTF 212
 QY 183 IHVPVGCTCVLPRSV 197
 DB 213 IHVPVGCTCVLPRSV 227
 RESULT 31
 AAE08703
 ID AAE08703 standard; Protein; 227 AA.
 AC AAE08703;
 XX 15-NOV-2001 (first entry)
 DT Human interleukin (IL)-17 like protein mutant (Cys221Ala).
 DE Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
 KW multiple sclerosis; graft versus host disease; inflammatory disease;
 KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
 KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
 KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 221 /note= "Wild-type Cys substituted with Ala"
 FT
 XX WO200159120-A2.
 XX 16-AUG-2001.
 XX 07-FEB-2001; 2001WO-US03916.
 XX 08-FEB-2000; 2000US-0180864.
 PR 27-NOV-2000; 2000US-0722920.
 XX (AMGE-) AMGEN INC.
 XX
 XX Jing S, Bass MB;
 DR WPI; 2001-529841/58.
 XX Novel interleukin-17 like polypeptides and nucleic acid molecules
 PT encoding them useful for diagnosis, prevention and treatment of
 PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
 PT rejection -
 XX
 Claim 27; Page -: 117pp; English.
 XX The present invention relates to interleukin (IL)-17 like polypeptides
 CC and nucleic acids encoding them. IL-17 like protein is useful for
 CC identifying binding partners, agonists and antagonists which can be used

CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Cys221Aa).
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.

XX SQ Sequence 227 AA;

Query Match 98.2%; Score 1054; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 6.7e-107; Indels 0; Gaps 0;
Matches 194; Conservative 0; Mismatches 1;
Qy 3 LLPGLLFTLWLTCLAHHDPSLRGHPHSHGTPHCYSABEPLGQAPPHLLARGAKWGQAL 62
Db 33 llpgllflftwlhtclahhdpslrghphshgtpchysaeelpgqapphllargakwgqal 92
Qy 63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHORSISPWRYRVDTDDEDRYPQ 122
Db 93 pvalvssleaaashrgrherpsattqcpvlrpeevleadthgrsispwryrvdtdedrypq 152
Qy 123 KLAFAECLRCGICDARTGRETAALNSVRLQSLVLRPRPCSRDGSGLPTPGAFAPHFTEF 182
Db 153 klafaeclrcgcidartgreetaalnsvrlqslvlrrprpcsdrgsglptpgafafhtef 212
Qy 183 IHVPVGCCTCVLPVRSV 197
Db 213 ihvpvgctavlprsv 227

RESULT 32
AAE08692
ID AAE08692 standard; Protein; 227 AA.

XX AC AAE08692;

XX DT 15-NOV-2001 (first entry)

DE Human interleukin (IL)-17 like protein mutant (Cys159Ser).

KW Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.

OS Homo sapiens.
OS Synthetic.

XX Key Location/Qualifiers
FH Misc-difference 159
FT /note= "Wild-type Cys substituted with Ser"

XX WO200159120-A2.

XX 16-AUG-2001.
PD 07-FEB-2001; 2001WO-US03916.
PF 08-FEB-2000; 2000US-0180864.
PR 27-NOV-2000; 2000US-0722920.
XX (AMGE-) AMGEN INC.
XX Jing S. Bass MB;
XX WPI; 2001-529841/58.
XX Novel interleukin-17 like polypeptides and nucleic acid molecules
XX encoding them useful for diagnosis, prevention and treatment of
XX inflammatory, autoimmune disease, allergies, asthma and organ or graft
XX rejection -
XX Claim 22; Page -; 117pp; English.
XX The present invention relates to interleukin (IL)-17 like polypeptides
XX and nucleic acids encoding them. IL-17 like protein is useful for
XX identifying binding partners, agonists and antagonists which can be used
XX for treating one or more diseases or disorders and for cloning IL-17
XX like receptors, using an expression cloning strategy. Radiolabelled or
XX affinity/activity-tagged IL-17 proteins are useful in binding assays to
XX identify a cell type or cell line or tissue that express IL-17 like
XX receptors. A radiolabelled or tagged IL-17 like protein is useful as an
XX affinity ligand to identify and isolate from an expression library the
XX subset of cells which express the IL-17 like receptors on their surface.
XX IL-17 like protein, agonist and antagonist are useful for treating acute
XX and chronic inflammation such as rheumatic diseases, graft versus host
XX disease and multiple sclerosis. IL-17 like antagonists are useful for
XX treating and preventing inflammatory disease, autoimmune disease,
XX allergies, asthma and organ or graft rejection in a patient and also
XX for inhibiting T cell proliferation and/or activation, in vivo B cell
XX proliferation or immunoglobulin secretion, and for blocking the effects
XX of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
XX gene therapy and for mapping the location of the IL-17 like gene and
XX related genes on chromosomes, as hybridisation probes in diagnostic
XX assays. Non-human animals in which the promoter for one or more of IL-17
XX like protein is either activated or inactivated are useful for drug
XX candidate screening. The present sequence is human IL-17 like
XX protein mutant (Cys159Ser).
XX Note: The present sequence is not shown in the specification, but is
XX derived from the human IL-17 like protein referred to as SEQ ID NO:2
XX (AAE08676), shown in figure 1A.

XX SQ Sequence 227 AA;

Query Match 98.1%; Score 1053; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 8.6e-107; Indels 0; Gaps 0;
Matches 194; Conservative 0; Mismatches 1;

Qy 3 LLPGLLFTLWLTCLAHHDPSLRGHPHSHGTPHCYSABEPLGQAPPHLLARGAKWGQAL 62
Db 33 llpgllflftwlhtclahhdpslrghphshgtpchysaeelpgqapphllargakwgqal 92
Qy 63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHORSISPWRYRVDTDDEDRYPQ 122
Db 93 pvalvssleaaashrgrherpsattqcpvlrpeevleadthgrsispwryrvdtdedrypq 152
Qy 123 KLAFAECLRCGICDARTGRETAALNSVRLQSLVLRPRPCSRDGSGLPTPGAFAPHFTEF 182
Db 153 klafaeclrcgcidartgreetaalnsvrlqslvlrrprpcsdrgsglptpgafafhtef 212
Qy 183 IHVPVGCCTCVLPVRSV 197
Db 213 ihvpvgctavlprsv 227

RESULT 33
AAE08694
ID AAE08694 standard; Protein; 227 AA.
XX AC AAE08694;
XX DT 15-NOV-2001 (first entry)
XX Human interleukin (IL)-17 like protein mutant (Cys161Ser).
DE DE
XX Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX OS Homo sapiens.
OS Synthetic.
XX FH Key Location/Qualifiers
XX Misc-difference 161 /note= "Wild-type Cys substituted with Ser"
XX WO200159120-A2.
XX 16-AUG-2001.
XX 07-FEB-2001; 2001WO-US03916.
XX 08-FEB-2000; 2000US-0180864.
XX 27-NOV-2000; 2000US-0722920.
XX (AMGE-) AMGEN INC.
XX Jing S, Bass MB;
XX WPI; 2001-529841/58.
XX Novel interleukin-17 like polypeptides and nucleic acid molecules
XX encoding them useful for diagnosis, prevention and treatment of
XX inflammatory, autoimmune disease, allergies, asthma and organ or graft
XX rejection -
XX Claim 23; Page -; 117pp; English.
XX The present invention relates to interleukin (IL)-17 like polypeptides
XX and nucleic acids encoding them. IL-17 like protein is useful for
XX identifying binding partners, agonists and antagonists which can be used
XX for treating one or more diseases or disorders and for cloning IL-17
XX like receptors, using an expression cloning strategy. Radiolabelled or
XX affinity/activity-tagged IL-17 proteins are useful in binding assays to
XX identify a cell type or cell line or tissue that express IL-17 like
XX receptors. A radiolabelled or tagged IL-17 like protein is useful as an
XX affinity ligand to identify and isolate from an expression library the
XX subset of cells which express the IL-17 like receptors on their surface.
XX IL-17 like protein, agonist and antagonist are useful for treating acute
XX and chronic inflammation such as rheumatic diseases, graft versus host
XX disease and multiple sclerosis. IL-17 like antagonists are useful for
XX treating and preventing inflammatory disease, autoimmune disease,
XX allergies, asthma and organ or graft rejection in a patient and also
XX for inhibiting T cell proliferation and/or activation, in vivo B cell
XX proliferation or immunoglobulin secretion, and for blocking the effects
XX of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
XX gene therapy and for mapping the location of the IL-17 like gene and
XX related genes on chromosomes, as hybridisation probes in diagnostic
XX assays. Non-human animals in which the promoter for one or more of IL-17
XX like protein is either activated or inactivated are useful for drug
XX candidate screening. The present sequence is human IL-17 like
XX protein mutant (Cys161Ser).
XX Note: The present sequence is not shown in the specification, but is
XX derived from the human IL-17 like protein referred to as SEQ ID NO:2
XX (AAE08676), shown in figure 1A.

SQ Sequence 227 AA;
Query Match 98.1%; Score 1053; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. NO. 8.6e-107;
Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3 LLPGLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
DB 33 LLPGLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 92
QY 63 PVALVSSLEAASHRGHERPSATTQCPLRPEEVLEADTHORSISPRYRVDTDEDYPO 122
DB 93 PVALVSSLEAASHRGHERPSATTQCPLRPEEVLEADTHORSISPRYRVDTDEDYPO 152
QY 123 KLAFAECLRCGCDARTGRTAALNSVRLQLSLVLRERRPCSRDGSGLPTPGAFAPHTF 182
DB 153 KLAFAECLRCGCDARTGRTAALNSVRLQLSLVLRERRPCSRDGSGLPTPGAFAPHTF 212
QY 183 IHVPVGCTCVLPRSV 197
DB 213 ihvpvgctcvlprsv 227
RESULT 34
AAE08696
ID AAE08696 standard; Protein; 227 AA.
XX AC AAE08696;
XX DT 15-NOV-2001 (first entry)
XX Human interleukin (IL)-17 like protein mutant (Cys164Ser).
DE DE
XX Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX OS Homo sapiens.
OS Synthetic.
XX FH Key Location/Qualifiers
XX Misc-difference 164 /note= "Wild-type Cys substituted with Ser"
XX WO200159120-A2.
XX 16-AUG-2001.
XX 07-FEB-2001; 2001WO-US03916.
XX 08-FEB-2000; 2000US-0180864.
XX 27-NOV-2000; 2000US-0722920.
XX (AMGE-) AMGEN INC.
XX Jing S, Bass MB;
XX WPI; 2001-529841/58.
XX Novel interleukin-17 like polypeptides and nucleic acid molecules
XX encoding them useful for diagnosis, prevention and treatment of
XX inflammatory, autoimmune disease, allergies, asthma and organ or graft
XX rejection -
XX Claim 24; Page -; 117pp; English.
XX The present invention relates to interleukin (IL)-17 like polypeptides
XX and nucleic acids encoding them. IL-17 like protein is useful for
XX identifying binding partners, agonists and antagonists which can be used
XX for treating one or more diseases or disorders and for cloning IL-17

CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Cys164Ser).
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.
XX
SQ Sequence 227 AA;

Query Match 98.1%; Score 1053; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 8.6e-107;
Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3 LLPGLLFTWLHTCLAHDPDLRSHGTPHCYSABEPLGQAPPHLLARGAKWGQAL 62
Db 33 LLPGLLFTWLHTCLAHDPDLRSHGTPHCYSABEPLGQAPPHLLARGAKWGQAL 92
Qy 63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHORSTSPWRYRYVDTDEDYPPQ 122
Db 93 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHORSTSPWRYRYVDTDEDYPPQ 152
Qy 123 KLAFACLCRCGIDARTGRETAALNSVRLQLSLVLRPPCRSDGSLPTPGAFAFHTEF 182
Db 153 KLAFACLCRCGIDARTGRETAALNSVRLQLSLVLRPPCRSDGSLPTPGAFAFHTEF 212
Qy 183 IHVPVGCCTCVLPVRSV 197
Db 213 ihvpvgctcvlprsv 227

RESULT 35

AAE08698
ID AAE08698 standard; Protein: 227 AA.

AC AAE08698;

DT 15-NOV-2001 (first entry)

DE Human interleukin (IL)-17 like protein mutant (Cys193Ser).

KW Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.

OS Homo sapiens.

OS Synthetic.

FH Key Location/Qualifiers

FT Misc-difference 193

FT /note= "Wild-type Cys substituted with Ser"

PN WO200159120-A2.

XX

PD 16-AUG-2001.
XX
PF 07-FEB-2001; 2001WO-US03916.
XX
PR 08-FEB-2000; 2000US-0180864.
PR 27-NOV-2000; 2000US-0722920.
XX
PA (AMGE-) AMGEN INC.
XX
PI Jing S, Bass MB;
XX
XX WPI: 2001-529841/58.
DR Novel interleukin-17 like polypeptides and nucleic acid molecules
XX encoding them useful for diagnosis, prevention and treatment of
XX inflammatory, autoimmune disease, allergies, asthma and organ or graft
XX rejection.
XX
PS Claim 25; Page -: 117pp; English.
XX
CC The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Cys193Ser).
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.
XX
SQ Sequence 227 AA;

Query Match 98.1%; Score 1053; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 8.6e-107;
Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 LLPGLLFTWLHTCLAHDPDLRSHGTPHCYSABEPLGQAPPHLLARGAKWGQAL 62
Db 33 LLPGLLFTWLHTCLAHDPDLRSHGTPHCYSABEPLGQAPPHLLARGAKWGQAL 92
Qy 63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHORSTSPWRYRYVDTDEDYPPQ 122
Db 93 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLADTHORSTSPWRYRYVDTDEDYPPQ 152
Qy 123 KLAFACLCRCGIDARTGRETAALNSVRLQLSLVLRPPCRSDGSLPTPGAFAFHTEF 182
Db 153 KLAFACLCRCGIDARTGRETAALNSVRLQLSLVLRPPCRSDGSLPTPGAFAFHTEF 212
Qy 183 IHVPVGCCTCVLPVRSV 197
Db 213 ihvpvgctcvlprsv 227

RESULT 36

AAE08700
ID AAE08700 standard; Protein; 227 AA.
XX
AC AAE08700;
XX
XX 15-NOV-2001 (first entry)
XX
XX Human interleukin (IL)-17 like protein mutant (Cys219Ser).
XX
XX Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Misc-difference 219 /note= "Wild-type Cys substituted with Ser"
FT
XX
XX WO200159120-A2.
XX
XX 16-AUG-2001.
XX
XX 07-FEB-2001; 2001WO-US03916.
XX
XX 08-FEB-2000; 2000US-0180864.
PR
PR 27-NOV-2000; 2000US-0722920.
XX
XX (AMGE-) AMGEN INC.
XX
XX Jing S, Bass MB;
XX
XX WPI; 2001-529841/58.
XX
XX Novel interleukin-17 like polypeptides and nucleic acid molecules
PT encoding them useful for diagnosis, prevention and treatment of
PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT rejection
XX
XX Claim 26; Page -; 117pp; English.
XX
XX The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Cys219Ser).
CC
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.
XX
XX Sequence 227 AA;

Query Match 98.1%; Score 1053; DB 22; Length 227;
Best Local Similarity 99.5%; Pred. No. 8.6e-107;
Matches 194; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGOAL 62
DB 33 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGOAL 92
QY 63 PVALVSSLEAASHRGHERSATTTQCPVLRPEEVLEADTHQRSISPRRYRVDTDDEYPO 122
DB 93 PVALVSSLEAASHRGHERSATTTQCPVLRPEEVLEADTHQRSISPRRYRVDTDDEYPO 152
QY 123 KLAFAECLRCGICDARTGRTAALNSVRLQSLVLRPPCRSDGSLPTPGAFAFHTEF 182
DB 153 KLAFAECLRCGICDARTGRTAALNSVRLQSLVLRPPCRSDGSLPTPGAFAFHTEF 212
QY 183 IHVPVGCTCVLPKRSV 197
DB 213 ihvpvgstcvlprsv 227
RESULT 37
AAE08702
ID AAE08702 standard; Protein; 227 AA.
XX
AC AAE08702;
XX
XX 15-NOV-2001 (first entry)
XX
XX Human interleukin (IL)-17 like protein mutant (Cys221Ser).
XX
XX Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Misc-difference 221 /note= "Wild-type Cys substituted with Ser"
FT
XX
XX WO200159120-A2.
XX
XX 16-AUG-2001.
XX
XX 07-FEB-2001; 2001WO-US03916.
XX
XX 08-FEB-2000; 2000US-0180864.
PR
PR 27-NOV-2000; 2000US-0722920.
XX
XX (AMGE-) AMGEN INC.
XX
XX Jing S, Bass MB;
XX
XX WPI; 2001-529841/58.
XX
XX Novel interleukin-17 like polypeptides and nucleic acid molecules
PT encoding them useful for diagnosis, prevention and treatment of
PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT rejection
XX
XX Claim 26; Page -; 117pp; English.
XX
XX The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Cys219Ser).
CC
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.
XX
XX Sequence 227 AA;

RESULT	39	
ID	AA053890	
AC	AA053890 standard; Protein; 87 AA.	
XX		
XX	AA053890;	
XX		
XX	13-MAR-2000 (first entry)	
XX		
DE	Human amino acid sequence of human interleukin-21.	
XX		
XX	Human: interleukin-21; IL-21; IL-22; immune system disorder;	
KW	immune cell chemotaxis; haematopoietic cell disorder;	
KW	haemostatic activity; thrombolytic activity; autoimmune disorder; asthma;	
KW	allergic asthma; respiratory problem; organ rejection;	
KW	graft-versus-host disease; GVHD; inflammation;	
KW	hyperproliferative disorder; tissue regeneration;	
KW	embryonic stem cell differentiation; embryonic stem cell proliferation;	
KW	haematopoietic lineage.	
XX		
OS	Homo sapiens.	
XX		
FH	Key	Location/Qualifiers
FT	Domain	3..11
FT		/note= "conserved domain I"
FT	Domain	19..24
FT		/note= "conserved domain II"
FT	Domain	46..52
FT		/note= "conserved domain III"
FT	Domain	75..82
FT		/note= "conserved domain IV"
XX		
PN	W09961617-A1.	
XX		
XX	02-DEC-1999.	
PD		
XX		
XX	27-MAY-1999; 99WO-US11644.	
XX		
PR	29-MAY-1998; 98US-0087340.	
XX		
PR	10-SEP-1998; 98US-0099805.	
XX		
XX	30-APR-1999; 99US-0131965.	
XX		
XX	(HUMA-) HUMAN GENOME SCI INC.	
PA		
XX		
PI	Ruben SM, Ebner R;	
XX		
DR	WPI: 2000-072622/06.	
DR	N-PSDB; AA236834.	
XX		
XX	Novel polynucleotides used to develop products for treating e.g. immune	
PT	disorders, blood disorders, autoimmune disorders, allergies,	
PT	inflammation, hyperproliferative disorders or infections -	
XX		
PS	Claim 25; Fig 1; 170pp; English.	
XX		
XX	The present sequence represents a partial human interleukin-21 (IL-21)	
CC	protein. The specification also describes IL-22 polynucleotides and	
CC	polypeptides. The IL-21 polynucleotide was isolated from a cDNA library	
CC	of apoptotic T-cells. IL-21 and IL-22 may be useful in treating or	
CC	deficiencies or disorders of the immune system, by activating or	
CC	inhibiting the proliferation, differentiation, or mobilization	
CC	(chemotaxis) of immune cells, treating or detecting deficiencies or	
CC	disorders of haematopoietic cells, to modulate haemostatic or	
CC	thrombolytic activity, in treating or detecting autoimmune disorders,	
CC	treating asthma (particularly allergic asthma) or other respiratory	
CC	problems, to treat and/or prevent organ rejection or graft-versus-host	
CC	disease (GVHD), to modulate inflammation, to treat or detect	
CC	hyperproliferative disorders, to treat or detect infectious agents, to	
CC	differentiate, proliferate and attract cells, leading to the regeneration	
CC	of tissues, IL-21 and IL-22 may also increase or decrease the	
CC	differentiation or proliferation of embryonic stem cells and	
CC	haematopoietic lineage, may be used to modulate mammalian	
CC	characteristics.	
XX		

CC minute biological samples, as an alternative to restriction fragment
CC length polymorphism (RFLP) analysis, as polymorphic markers for forensic
CC purposes, as molecular weight markers, or as diagnostic probes. IL-21 and
CC IL-22 polypeptides can be used to treat, prevent or diagnose diseases of
CC the immune system by activating or inhibiting the proliferation,
CC differentiation or mobilization of immune cells, disorders of
CC hematopoietic cells (e.g. ataxia, human immunodeficiency virus (HIV)
CC infection, anemia, thrombocytopenia), autoimmune disorders (e.g. Grave's
CC disease, systemic lupus erythematosus, ophthalmia), graft versus host
CC disease, inflammation, hyperproliferative disorders, or infectious
CC diseases. The polypeptides are useful for generating antibodies, which
CC can be used to treat, inhibit or prevent diseases or conditions
CC associated with aberrant expression and/or activity of IL-21 or IL-22.
CC The present sequence represents the partial amino acid sequence of human
CC IL-21.
xx

SQ Sequence 87 AA;

Query Match 42.8%; Score 459; DB 22; Length 87;
Best Local Similarity 100.0%; Pred. No. 2.1e-42;
Matches 86; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 112 RVDTEDEYPOKLAFAECLCRGCDARTGRTAALNSVRLQLSLVLRPRCSRDSGLP 171
Db 2 rvdtdedrypqklafaeclcrgcdartgretaalnsvrlqlslvlrrprcsrdsgslp 61
Qy 172 TPGAFARHTFEIHVPVGCTCVLPKRSV 197
Db 62 tpgafafhtfeihvpvgctcvlprsv 87

Search completed: September 16, 2002, 15:45:32
Job time: 236 sec